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Abstract
Delayed drug hypersensitivity reactions (DHRs) are idiosyncratic, T-cell mediated, and can
present days after exposure to the culprit drug, resulting in varying degrees of skin rashes.
We hypothesize that differences in activated peripheral T cell subsets and types of mediators
released produce different clinical phenotypes of drug hypersensitivity reactions to
sulphnamides and beta-lactam antibiotics.
We recruited participants with previous DHRs to sulfamethoxazole or beta-lactams .
Peripheral blood mononuclear cells were isolated from participants. T-cell subset
proliferation and activation was assessed by T-cell specific surface markers using 3Hthymidine incorporation and flow cytometry, and secreted cytokines were measured using
bead-based detection.
There is insufficient evidence to conclude which T-cell subtypes are involved in different
DHR clinical presentations. There were no significant differences between DHR participants
and controls. More participants should be recruited to increase study power and range of
clinical presentations, and consider alternate methods of identifying T-cells and modulators
of interest.
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Summary for Lay Audience
Delayed drug hypersensitivity reactions (DHRs) are reactions that are somehow caused by
the immune system interacting with the drug. DHRs typically occur days after taking the
drug, usually result in a skin rash, and are mediated by T cells. It is still unclear how the T
cells cause DHRs, however there are several theories. Two commonly prescribed drugs that
cause these reactions are sulfamethoxazole and beta-lactam antibiotics. We believe that
reactions mediated by different types of T cells in the blood lead to the various types of skin
rashes caused by DHRs.
We recruited participants who had previously visited Dr. Rieder’s drug allergy clinic and had
previously tested positive for a DHR to either sulfamethoxazole or beta-lactams. We took a
sample of blood from each participant, isolated a group of blood cells from the samples
called “peripheral blood mononuclear cells” (PBMCs), which contains T cells. We tested
these cells in different ways to see how the cells were responding to the drug. We used a
technique called scintillation counting to determine if the PBMCs were growing when
incubated with the drug, flow cytometry to see which type of T cell was activated in response
to the drug, and Luminex to determine which molecules (cytokines) the PBMCs produced
after incubation.
We have insufficient evidence to conclude which type of T cell is involved in each skin
reaction. Overall, we found no differences between T cell subset activation in response to
exposure to the drug treatment, while other studies have previously found differences.
Changes in the methods, including increasing number of T cells used in the analysis and
expanding the number of T cell subsets analyzed by flow cytometry, and increasing the
cytokines analyzed by Luminex, could improve results. We only recruited eight participants,
to increase the strength of the conclusions we will need to increase the number of
participants. We conclude that some changes in methods could improve and produce more
reliable results.
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Introduction

Drugs and medications are an important part of care for many patients, including some of
our population’s most vulnerable and sick. However, while many individuals can take a
drug and benefit from its therapeutic effects, some can experience harmful and
potentially fatal reactions. Adverse drug reactions cause a number of problems, which in
addition to the effects on the health of the patient can include unexpected effects due to
suspected risk of adverse drug reactions including mis-labeling, use of less effective
medications and overuse of other types of drugs such as antibiotics leading to resistance.

1.1 Background Information
1.1.1

Definitions

There have been many definitions suggested for adverse drug reactions (ADR) since the
World Health Organization (WHO) published their definition in 1972. Specifically, a
drug reaction is classified as adverse when, taken at a standard dose, it causes a noxious
and unintended reaction.1 The WHO also defines a drug as a substance or product whose
use can benefit the recipient either physiologically or psychologically.1
An adverse drug event is an undesired outcome that occurs while a patient is taking a
drug, but the adverse outcome is not necessarily attributable to the drug, for example an
overdose. This is different from an adverse drug effect, which is an adverse outcome that
can be attributed to some action of the drug the patient took, an example being a side
effect.2
The term “drug allergy”, however, is often used out of context to describe conditions that
are not mechanistic allergies.3 This unhelpful labeling has prompted Johansson et al. to
suggest revised nomenclature for mechanistic discussions on ADRs.4 They recommend
the term ‘hypersensitivity’ be used to describe reproducible signs or symptoms due to
exposure to a stimulus at a dose that is normally tolerated. They also recommend the term
‘allergy’ be used only to describe a hypersensitivity reaction that has a specific and
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defined immunologic mechanism. When there are other mechanisms that are not
immune-mediated, then non-allergic hypersensitivity can be used.

1.1.2

Prevalence

Adverse drug reactions are a burden on the individual and expensive to the health care
system. In 1994 it was estimated that in the United States 106 000 patients died of
2,216,000 hospitalized with ADRs as a result of a drug injury.5 ADRs are responsible for
approximately 5% of all hospital admissions and affected 10-20% of all hospital
inpatients. In addition to the burden placed on physicians and the healthcare system,
ADRs increase the cost of an individual’s care and negatively affect their quality of life.6–
10

1.1.3

Economic Impact

Of all ADRs, approximately 20% are drug hypersensitivity reactions (DHRs).11,12 Many
people in the USA (20-35%) report having at least one prior reaction to medication.11,13,14
However, not all of these reported reactions are true ADRs: only 1-5% of people with a
reported drug allergy actually have one.11,15 This overreporting can compromise patient
care, including the prescribing of less effective treatment options and potentially
increasing the cost of care. For example, using alternative antibiotics has been associated
with increased treatment failures and higher rates of nosocomial infections (eg.
Methicillin resistant Staphylococcus aureus, MRSA).11,16,17 People who report penicillin
allergy also spend longer times in hospital than non-allergic patients,11,18 and have higher
costs associated with their prescription medications.11,19–22 Treating ADRs is expensive,
potentially costing thousands of dollars to treat.11,23 Based on a report from Canada,
performing graded oral challenges in children before prescribing antibiotics based on
reported allergy is able to save money.11,24

1.1.4

Difficulties and Considerations in Diagnosing ADRs

Accurate, reliable, and safe tests are important for both predicting and confirming ADRs.
Currently, the risks for many ADRs are overestimated, particularly with reactions to
penicillin. In a recent survey,25 approximately 65% of surveyed patients responded they
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would not continue to use a drug even if told by their physician that the reaction was not
caused by the drug in question. A penicillin allergy is the most common drug allergy
charted during hospital admissions and has been linked to increased time in hospital;
increased reliance on broad-spectrum antibiotics; and increased prevalence of
Clostridium difficile, MRSA, and vancomycin-resistant Enterococcus infections.26 There
are consequences of overdiagnosis of drug allergy, including an increase in drug-resistant
infections.3,18,27 However, there is no consensus on the extent of over-diagnosis. Drug
allergies are often self-reported, and the frequency can be as high as 39%.3,28 Sousa-Pinto
et al., after completing a meta-analysis, found that 8.3% of their participants had selfreported a drug allergy.3
In addition to overcoming personal conviction, accurate diagnoses are also important, as
inaccurate diagnoses prevent patients from being treated with potentially beneficial
drugs. However, the opposite of this is also true. If a patient is told they are not sensitive
to a drug and is then treated with the drug, they could be subjected to a potentially fatal
and avoidable reaction.29,30 Adverse drug reactions can also present similarly to other
diseases, so it can be difficult to discriminate between the illnesses.30 Some drug-induced
rashes can be indistinguishable from rashes produced by other agents, such as viruses.31
ADRs and DHRs typically affect more children and women than men, for reasons that
can either be physiological or sociological. Women are prescribed more antibiotics than
men. In a meta-analysis across nine high-income countries, women in general across all
ages are 27% more likely to receive an antibiotic, and up to 40% more likely in the 16-54
age group.32 In the USA specifically, women are prescribed more antibiotics for
respiratory tract infections (RTIs) than men are.32,33 In England in 2019, an analysis by
Smith et al. found that adult women receive almost twice as many antibiotic prescriptions
than men, while elderly women specifically receive 67.4% more.34 They also note some
drugs are simply more commonly prescribed to women than men, however there is still a
disparity of 70% more prescriptions when urinary tract infections (UTIs) are removed
from the analysis. In addition to being prescribed more antibiotics alone, women are
more likely to consult with their general practitioner (GP) more than men. In the USA,
men visit their GP less, but also exhibit more risk-taking and health-compromising
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behaviours and conditions than women do, including obesity, smoking, and drinking.32
Smith et al. describe women seeking primary care 80% more than men across the 12
conditions they examined.34
In addition to utilization differences in prescribing, there are potentially pharmacological
differences in women compared to men that would lead to an increased incidence of
ADRs. For example, Rademaker demonstrated that cytochrome P450 (CYP45) 3A4 is
higher in women by up to 40%, which they attribute to different steroid hormones
affecting CYP3A4 activity due to competitive inhibition.35,36 The author suggests that
metabolites generated due to drug metabolization by CYP3A4 might be the cause of the
ADRs. Rademaker also noted the differences in conjugation of drugs between men and
women – specifically referencing temazepam, which is conjugated and cleared faster in
men than women.35,37 Kando observed that women have higher concentrations of drug in
plasma than men and receive more drug due to a smaller body mass.38 In addition, Kando
reviewed how hormones can also have an influence on ADRs affecting more women.38
Different levels of estrogen, progesterone, and testosterone may affect enzyme activity
throughout the menstrual cycle, which can affect the metabolization of drugs.38

1.2 Classification of ADRs
The most common classification system for ADRs divides ADRs into two main types:
Type A and Type B. Type A reactions, the most common, are predictable since the
reaction is related to the known pharmacological action of the drug. These reactions are
dose-dependent and essentially exhibit amplified effects of the drug. By reducing the
dose or eliminating the drug from the patient’s therapy, the reaction can often be
reversed. Type B reactions, however, are generally more unpredictable due to the
potential for delayed onset of signs and symptoms. These often do not exhibit a dosedependent relationship and the effects are not usually related to the known drug
pharmacology.39 Type B, or “idiosyncratic adverse drug reactions,” are further
subdivided into two groups: immune-mediated, or hypersensitivity reactions, and nonimmune mediated reactions. A breakdown of this classification is outlined in Figure 1-1.

5

1.2.1

Non-Immune Mediated Reactions

Pseudoallergy is another term for a reaction that is clinically a hypersensitivity but is not
immune-mediated. It is classified here because these reactions imitate other reactions and
can range from being mild to causing anaphylaxis.40 While pseudoallergy can be similar
to anaphylaxis, unlike anaphylaxis, pseudoallergy results from mast cells and basophils
releasing mediators. This process is not mediated by immunoglobulin E (IgE).41,42 This
leads to histamine release, complement activation, among others.41,43 One example of this
is vancomycin-induced redman syndrome. Mast cells and basophils degranulate,
releasing histamine, in a manner which is not IgE-dependent,44 resulting in a flushed face,
neck, and ears, and is often accompanied by itching.45

1.2.2

Immune-Mediated Reactions

These reactions have been further divided into subtypes. These were originally outlined
by Gell and Coombs46 and have been modified slightly by the addition of further
subclassifications.
Type I
Type I reactions are mediated by IgE, bound to mast cells with Fc-IgE receptors. The
mast cells release histamine and cause an immediate reaction, including urticaria and
fatal anaphylaxis. The reaction can start within seconds of a parentally applied drug, or
within minutes of oral intake. Most of these reactions result in pruritis or urticaria,
however they can escalate to life-threatening reactions such as anaphylaxis.40
Type II
Type II reactions involve the formation of complement-fixing IgG antibodies and
occasionally IgM that interact with Fc-IgG receptors on macrophages, natural killer (NK)
cells, granulocytes, etc. In these reactions, immune complex activation occurs on the cell
surface of erythrocytes, leukocytes, platelets, hematopoietic precursor cells, etc.40 There
are several ways in which this can occur, including opsonization of cells by activated
complement components leading to phagocytosis, antibody deposition leading to
macrophage and neutrophil recruitment, and anti-body-dependent cell-mediated
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cytotoxicity due to eosinophil degranulation.47 Pichler proposes that, specifically to
drugs, the drug can be adsorbed to the membrane, creating a new antigenic complex with
the cell membrane.40 Hemolytic anemia and thrombocytopenia have been listed as side
effects to various drugs, including penicillin, cephalosporins, quinidine for the former,
and quinine, quinidine, and sulphonamides for the latter.40
Type III
In Type III reactions, immune complexes are formed, which is a common event in a
normal immune response and does not typically result in symptoms. Efficiency of
treatment can decrease if immune complexes are formed by drug-protein interactions. It
is not fully understood why an immune complex disease forms, and several reasons can
be speculated as to why these occur. An inability to remove complexes can result in
inappropriate deposition, leading to recruitment of other immune cells, leading to
hypersensitivity, small vessel vasculitis and/or serum sickness.40
Type IV
Type IV are T cell mediated hypersensitivity reactions. Originally, Gell and Coombs did
not subclassify these reactions, however with new knowledge of the functions of T cells
and the types of inflammation they cause, these reactions have been further subclassified
from Type IVa to Type IVd.40
Type IVa: These are Th1-type immune reactions, involving the activation of macrophages
by IFN-γ and complement-fixing antibody production. This can possibly lead to coactivation of CD8+ T cells, leading to a combination of Type IVa and IVc reactions.40
Type IVb: These are Th2-type immune reactions, with cytokines IL-4, -13, and -5 which
promote mast cell and eosinophil responses.40
Type IVc: T cells can migrate to the tissue and kill different cells with cytotoxic
molecules such as perforin and granzyme B. Cytotoxic T cells (CD8+ T cells) are
involved in maculopapular or bullous skin diseases, acute generalized exanthematous
pustulosis (AGEP), and contact dermatitis.40
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Type IVd: This reaction involves T cells coordinating neutrophilic inflammations in the
skin, such as in AGEP.40

Figure 1-1: Schematic of ADR classification

1.3 Pathophysiology of DHRs
There are several competing hypotheses that attempt to explain the mechanism that drives
T cell-mediated drug hypersensitivity reactions. Not all drug reactions support a singular
hypothesis, which led to the development of several hypotheses. These hypotheses are
modeled in Figure 1-2.
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Figure 1-1: Schematic of proposed hypotheses of DHR mechanisms
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1.3.1

The Hapten Hypothesis

The hapten/pro-hapten mechanism describes how small, low-molecular weight
compounds (<1000 D) are able to elicit an immune response.40,48–51 The concept of a
“hapten” driving an immune response was first published around 1935 by Landsteiner
and Jacobs. They theorized that small molecules themselves were not immunogenic, but
became immunogenic once bound to a protein.52 Subsequently the hapten hypothesis was
further elucidated. The hypothesis is essentially that a hapten binds to a carrier molecule
such as a protein and the modified hapten-carrier molecule can then generate an immune
response. Similarly, pro-haptens, which are not chemically reactive, are first metabolized
in the liver where they can then bind to a peptide.40,48,53–55 Beta-lactam antibiotic allergy
was felt to be an example of a drug reaction that followed the hapten mechanism. This
process occurs due to nucleophilic attack on the drug molecule, opening the beta-lactam
ring, resulting in a penicilloyl-protein adduct, which can cause an immune response.56,57
These drugs often bind to albumin as its carrier protein,58 since it is the most abundant
protein in serum.57

1.3.2

The P-I Hypothesis

A competing hypothesis is the p-i (direct pharmacological interaction of drugs with
immune receptors) hypothesis, that speculates that chemically inert drugs can activate T
cells via specific T cell receptors (TCRs) that interact with the specific drugs.40,48,49,59
This hypothesis postulates that the drug-TCR interaction is independent from metabolism
and processing. The drug binds to the TCR directly, and the major histocompatibility
complex (MHC) is not covalently modified. However, MHC binding is still required for
full T cell activation.60 The p-i hypothesis was developed in response to the
hapten/prohapten hypothesis stating that a low molecular weight drug must bind to a
protein to initiate an immune response, and contradicts the necessity of protein binding.
Specifically, Pichler considers how some chemically inert drugs, which cannot become
haptenized in the skin, result in positive skin tests.59–62
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1.3.3

The Danger Hypothesis

The danger hypothesis was proposed as an alternative to the self/non-self concept of
immune reactions. Injured cells send danger or alarm signals, which activate antigenpresenting cells (APCs).63 In this hypothesis, the immune system is triggered by damage
signals instead of recognizing non-self antigens.63–65 It is suggested that the drug or its
reactive metabolite must also cause cell damage for a drug reaction to occur.66 One
possibility is that during drug metabolization, accumulation of reactive metabolites can
lead to cell death, which generates danger signals.67 It has been suggested that there are
other factors that can act as a danger signal that would increase a patient’s chance of
having a drug reaction. Administering a patient with mononucleosis ampicillin will often
develop a skin rash.66,68 An example is the 50% chance of developing a drug reaction
when sulfamethoxazole administered to patients with AIDS versus 0.5% in uninfected
patients.66,69

1.3.4

The Altered Repertoire Hypothesis

The altered repertoire hypothesis describes how a drug can interact with human leukocyte
antigen (HLA) class I molecules, leading to the presentation of altered peptides that can
cause an immune reaction.70 There has recently been increasing support for this
hypothesis. As an example, abacavir is able to activate CD8+ cells in an HLA-B*57:01restricted manner, leading to a hypersensitivity reaction.71 After deducing that other
hypotheses could not support this observation, Ostrov et al. found that abacavir can bind
to the peptide binding groove of HLA-B*57:01 allowing for the presentation of novel
peptides that appear as foreign, triggering a response from CD8+ cells.72

1.3.5

Reactive Metabolite Hypothesis

The reactive metabolite hypothesis suggests that reactive metabolites of a drug are
responsible for drug reactions, instead of the parent drug.73 This can either be through
drug metabolism or if the drug damages a cell and produces danger signals.73 The
reactive metabolite of many drugs is responsible for its activity, and this typically occurs
during metabolization by enzymes in cells such as hepatocytes.74,75 Drug metabolites can
accumulate, resulting in an endogenous molecule that can then be taken up by antigen
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presenting cells and presented to T cells.74 One proposed example is the metabolic
pathway of sulfamethoxazole, which leads to reactive metabolites.73 This hypothesis has
been linked to the hapten hypothesis, in that reactive metabolite generation may be the
initial event triggering an immune response by the creation of a reactive metabolite that,
when complexed with a cellular macromolecule, acts as a hapten to generate an immune
response.76

1.4 Immune-Mediation of DHRs
The innate immune system (“pro-inflammatory” immune response) is responsible for
rapid recognition of an antigen. This system consists of neutrophils, macrophages,
monocytes, NK cells, dendritic cells (DCs), among others, which direct and inform the
adaptive immune system.77
The adaptive immune system is responsible for both specific and memory responses, and
is composed of B cells, αβ T cells, and γδ T cells. Upon recognizing or being presented
with an antigen, these cells expand to perform specific functions: B cells become plasma
cells, which make large quantities of immunoglobulins, and T cells (specifically αβ)
either directly kill cells or recruit other cell types. While most of these cells die after the
culmination of the immune response, some – such as memory T cells – continue to live
for many years in order to protect against reinfection after initial contact.77

1.4.1

Composition of PBMCs

Peripheral blood mononuclear cells (PBMC) are a cellular population that can be isolated
from peripheral blood, and essentially consist of any blood cell featuring a single round
nucleus, which include lymphocytes, monocytes, NK cells, and dendritic cells (DCs).78
These cells are separated from red blood cells, granulocytes (neutrophils, basophils, and
eosinophils) by density gradient separation, whereas PBMCs are located in the lowdensity layer (ie. less dense than 1.077 g/ml). Although there is some variability across
individuals, PBMCs are typically composed of approximately 70-90% lymphocytes, 1020% monocytes, and 1-2% DCs. Of the lymphocytes, approximately 70-80% are CD3+ T
cells, 5-10% B cells, and 5-20% NK cells. Typically within CD3+ lymphocytes, CD4+
and CD8+ cells are represented in a 2:1 ratio, respectively.78–82
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1.4.2

Antigen-Presenting Cells

Antigen-presenting cells (APCs) are cells at the overlap between the innate and acquired
immune systems. DCs, B cells, and macrophages are all considered to be professional
APCs. What distinguishes these APCs from other cells is the presence of abundant MHC
class II receptors. Specifically, DCs and macrophages can detect and phagocytose
substances (e.g. pathogen-associated molecular patterns (PAMPs), damage-associated
molecular patterns (DAMPs)), parts of apoptotic cells, process antigen, and move to
specific tissues (e.g. T cell zone of lymph node). B cells acquire antigen through the B
cell receptor (BCR).83
Some other cells, such as mast cells, basophils, eosinophils, neutrophils, innate lymphoid
cells (ILCs), and CD4+ T cells have also been found to be able to induce MHC class II
expression. However, this can only occur in certain immune environments and has not
been researched extensively to conclude their role.83

1.4.3

Dendritic Cells

DCs are antigen-presenting cells (APCs) that modulate the immune response by
stimulating B cells and T cells.84,85 These cells are located in most tissues throughout the
body. They are stellate and have a multiplicity of MHC molecules on their surface.84,86
There are two stages in the life of a DC: the immature and the mature stage. As an
immature DC, these cells have few MHC molecules, capture antigens (with Fcγ and Fcε),
but they cannot generate the appropriate stimulatory molecules for T cells (CD40, CD54,
CD86). Immature DCs are able to phagocytose particles,84,87–90 sample antigens in
phagocytic vesicles,84,91 and then express the appropriate receptors to stimulate T cells.
Mature DCs, however, are terminally differentiated, and display many MHC class II
molecules bound to antigen.84,92 They upregulate costimulatory molecules, then move to
secondary lymphoid tissues to interact with T cells.

1.4.4

B Cells

B cells are “bursal” or “bone marrow” derived cells that date back to the origin of
adaptive immunity in jawed vertebrates more than 500 million years ago.93,94 B cells
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originate in the primary lymphoid tissue, which in humans is the bone marrow. In
general, they undergo functional maturation in the spleen or lymph nodes, which are the
secondary lymphoid organs, and then finally produce antibodies as plasma cells. These
cells undergo functional rearrangement of Ig loci in the bone marrow: V, D, and J
sequences at the H chain locus and V and J at the L chain loci.93,95 These allow for a
diverse repertoire of B cell receptors in the B cell population.

1.4.5

T Cells

T cells have been previously shown to be involved with DHRs and it is believed that they
are the central driver for common and important DHRs.53,54,96–104 However, the role(s)
that different T cell subtypes and their mediators may have in the pathogenesis of Type
IV DHRs, if any, have not been fully explored, nor has the impact of different T cells
responses to clinical phenotypes of DHRs.

1.4.5.1

Helper T Cells

T helper cells (Th) are involved in the coordination of the adaptive immune response,
primarily by the secretion of specific cytokines to recruit other cells toward infected
areas. These cells are characterized by CD4+.105 Specific cytokine environments and
master regulators are responsible for the many subtypes of Th cells that have been
discovered.
Th1 Cells
T helper 1 (Th1) cells produce the cytokine interferon-γ (IFN-γ). They function to
eliminate intracellular pathogens and are involved in two types of hypersensitivity
reactions: cell-mediated and delayed.106,107 Additionally, Th1 cells are involved in the
process of producing opsonins, complement-fixing antibodies, and can lead to
macrophage activation.108
Both IFN-γ and interleukin-12 (IL-12) are the cytokines in a naïve T cell’s environment
that promote differentiation to Th1 subtype. IFN-γ inhibits Th2 cell differentiation while
IL-12 promotes Th1 growth and does not affect Th2 cells.109–112 T-bet is the transcription
factor that controls the expression of IFN-γ and is imperative for Th1 cell differentiation
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from naïve CD4+ T cells. T-bet both activates the IFN-γ gene as well as induces
exogenous production of IFN-γ.113 Th1 cells are found to be involved in organ-specific
immune disorders, acute allograft rejection, contact dermatitis, among other immune
disorders.108
IFN-γ
Th1 cells are defined by their secretion of IFN- γ, although many cells have been found to
secrete this cytokine, including B cells, natural killer T cells (NKT), and professional
APCs114–118 in addition to Th1, CD8+ T cells, and NK cells.114,119,120 Multiple studies have
found that IFN-y is secreted by PBMCs isolated from study participants with a history of
delayed type drug hypersensitivity. IFN-γ is secreted when drug-specific PBMCs are
incubated with sulfamethoxazole (SMX)121 and piperacillin.104 In addition, Beeler et al.
found that PBMCs from AGEP and severe exanthema patients secreted both IFN-γ and
interleukin-13 (IL-13).122
Th2 Cells
Another subset of helper T cells are T helper 2 (Th2) cells. These are associated with
extracellular (helminth) responses and stimulating damaged tissue repair. These secrete
IL-4, -5, -6, -9, -10, and -13.106–108
The cytokine IL-4 promotes the differentiation of a naïve CD4+ T cell to a Th2
cell.109,123,124 During Th2 development, the transcription factor GATA-3 is upregulated.
Conversely, it is downregulated during Th1 development.125–127
Th2 cells are mediators in a variety of different disorders such as Omenn’s syndrome,
reduced protection against extracellular pathogens, and chronic Graft vs. Host Disease.108
IL-4
IL-4 is a potent regulator of immunity,128 regulating immune functions such as Ig isotype
class switching, B cell MHC class II expression, and differentiating certain Th cell
lineages.129 IL-4 is also secreted by mast cells, eosinophils, and basophils in addition to
Th2 cells.128 It was first described by Howard and Paul as a comitogen of B cells.128,130
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IL-4 binds to IL-4R alpha. It can either produce type I signaling when also bound to
gamma chain or type II when bound to IL-13Rα1.128,131,132 This Type I signaling is
important for the polarization of naïve CD4+ T cells to Th2 cells.128
IL-13
IL-13 is a cytokine secreted by Th2 cells.106–108 It is able to induce the expression of MHC
class II in human B cells and phenotypic changes in human monocytes. It also acts on
human B cells by inducing proliferation and immunoglobulin production.133–136 In
general, IL-13 has anti-inflammatory properties and plays a regulatory role in the
immune response.
IL-13 is secreted by T cells when drug-specific PBMCs are stimulated with either
ampicillin (AMP) or SMX.137 It is also secreted by PBMCs from piperacillinhypersensitive patients when incubated with the culprit drug.104 Beeler et al. noted that
PBMCs of patients with severe exanthema and AGEP secreted IL-13 as well as IFN-γ.122
Th9 Cells
Th9 cells are generated by naïve CD4+ cells exposed to TGF-ß and IL-4, and are
characterized by their production of IL-9.138 In contrast, exposing naïve CD4+ cells to IL4 only leads to the differentiation of Th2 cells,138 and CD4+ cells to TGF-ß only leads to
induced regulatory T cells (Treg).138–141 While Th2 cells also produce IL-9, Th9 cells
produce IL-9 in much greater quantities and have a different role in the immune response
than Th2 cells.142 These cells also require transcription factors STAT6, PU.1, IRF4, and
GATA3.138,143–146 Although Th9 cells require such a specific environment to differentiate,
they do exist in vivo, and can be found in the peripheral blood of allergic patients147
among CLA+ (cutaneous leukocyte antigen positive) cells in the blood and skin.148,149
IL-9
Many cells are able to produce IL-9, including Th9 cells, innate lymphoid cells, mast
cells, and neutrophils.138,142,150–153 However, Th9 cells produce IL-9 in a greater quantity
than Th2.144,146 When T cells are activated by either PMA (phorbol myristate acetate) or
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anti-CD3, IL-9 expression can be induced,154 with the addition of IL-2 further
upregulating production.155 IL-9 promotes the survival of other cells, such as Th cells,
mast cells, among others.156–158 IL-9 is also able to expand Th17 and Treg cells.138,159–162
IL-9/Th9 cells have specifically been implicated in allergy and asthma. While IL-9 levels
are increased in asthmatic patients,163 it is unknown if it is involved in other instances of
allergy, such as anaphylaxis and atopic dermatitis.
Th17 Cells
T helper 17 (Th17) cells are a subset of Th cells that predominantly secrete IL-17. Th17
cells were the third Th subset discovered164–166 and target extracellular bacteria and fungi.
Interestingly, IL-17 was discovered before Th17 cells.167–169 When human naïve T cells
are exposed to IL-1B and IL-6, Th17 cells are differentiated.139,170,171 The transcription
factor important in the differentiation of Th17 cells is orphan nuclear receptor RORγt.172
IL-17 does not inhibit Th1 or Th2 cells,173 but IL-12, IFN-γ, and IL-4 inhibit Th17
cells.165,166,174–177
While Th17 cells are characterized by IL-17 production, they also produce IL-17F, IL-22,
and some TNF-α (tumour necrosis factor α), but IL-17A is predominant.164 Th17 cells
produce TNF-α, IL-21, and IL-22, while it is debated whether they produce IL6.106,171,178–180
Both Th17 cells and IL-17 have been implicated in several human diseases, including
psoriasis, rheumatoid arthritis, systemic lupus erythematosus, endometriosis, asthma,
irritable bowel syndrome, multiple sclerosis, atopic dermatitis, contact hypersensitivity,
among others. In atopic dermatitis specifically, acute atopic dermatitis is associated with
IL-17, but not chronically.164,181
IL-17
Th17 cells are a major producer of IL-17.106 IL-17 includes IL-17A, B, D, E, and F.182
The functions of IL-17A and F include targeting fibroblasts, endothelial and epithelial
cells, keratinocytes, macrophages, and stimulating and attracting neutrophils to
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inflammation.178,183 IL-17 is important in extracellular bacteria defense171 and in the
mobilization of neutrophils.169,171
Interestingly, a previous study has shown that when PBMCs isolated from piperacillinhypersensitive patients are incubated with piperacillin, no IL-17 is produced. However, it
is produced when incubated with PHA (phytohemagglutinin).104
Th22 Cells
Th22 cells are a terminally differentiated subtype of helper T cells that secrete IL-22. The
cytokine environment required for the differentiation of naïve CD4+ T cells to Th22 cells
is TNF-ß (tumour necrosis factor ß) and IL-6.184,185 The master regulator of Th22 cells is
aryl hydrocarbon receptor.185–187
Th22 cells were discovered due to their secretion of IL-22, but no signature cytokines of
other T cell subtypes, such as IFN-γ, IL-4, and IL-17.184,185,187,188 However they do
secrete small amounts of IL-13 and TNF-ß.184,188
IL-22
IL-22 is predominantly secreted by Th22 cells, but is also secreted in small amounts by
Th1, Th2, and Th17 cells184 and is a member of the IL-10 family of cytokines.186 IL-22
specifically binds to the IL-22 receptor (IL-22R), a heterodimeric receptor composed of
IL-10Rß and IL-22Rα chains, which is abundant on epithelial cells.184,189 Specifically, IL22R is expressed in skin, liver, pancreas, intestine, lung, and kidney.186,190–192 IL-22 is
also involved in wound healing.184,188,193
IL-22 is implicated in some skin rashes, which can be a symptom of a DHR. For
example, IL-22 is upregulated in psoriasis lesions.186,194–196 IL-22 is also found in greater
amounts in atopic186,197 and contact dermatitis lesions.186,198
Regulatory T cells (Treg)
The immune system has the dual role of simultaneously protecting the host from
pathogens or tumours while also preventing harm from excessive and harmful responses.
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If an immune response is misdirected, it can produce an autoimmune disease.79
Regulatory cells that act to prevent this are characterized as CD4+CD25+FoxP3+.139 Treg
cells are a dominant mechanism for preventing excessive response and are specialized for
immune suppression. Autoimmune and inflammatory responses can be caused by
disruptions in the development or function of Tregs. When an adaptive immune response is
occurring, both effector cells and Tregs are activated and recruited to the site of
inflammation to maintain a balanced immune response, in both the quality and magnitude
of the adaptive immune reaction.79
Previous work has demonstrated the importance of Tregs are in controlling the immune
response. Manipulating the thymus, as for example a thymectomy in a newborn, results in
autoimmune damage and compromised immunity.79 In addition, removing autoimmunesuppressive T cells from an organism can lead to autoimmune disease, while adding them
back inhibits autoimmunity.199
Regulatory T cells have many notable functions, but have important roles in inhibiting
autoimmunity and protecting against tissue injury.139,200 The cytokine TGF-ß is important
in differentiating naïve CD4+ T cells into Treg cells.139,201

1.4.5.2

Cytotoxic T Cells

Broadly, the role of a cytotoxic T lymphocyte (CTL) is to survey all nucleated body cells
and destroy any that are a threat.202 When peptides are formed within the cell due to
protein degradation, CTLs can detect the peptides when presented by MHC class I
molecules.203
A CTL needs to be in close contact to the target cell in order to kill it. The first
mechanism is binding of Fas on the target cell to Fas ligand (FasL) on the effector cell,
which transfers a death signal.204–206 The second method is performed through granule
exocytosis. In the presence of calcium (Ca2+), granules are exocytosed into the space
between the target and effector cells, causing holes to be formed within the target cell
membrane.207 Examples of these “granules” include perforin,208 and granzymes A and
B.209
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Perforin
Perforin is a protein involved in granule exocytosis in CTLs. Upon polymerization,
perforin forms pores in the membrane of a target cell.210,211 These pores then disrupt ion
gradients in a cell and result in osmotic lysis of the target cell.212,213 Both CTLs and NK
cells express perforin.210,214–216 Perforin has a major role in pathologies such as graft
rejection and immune responses against viruses.205,210,217,218 When Kagi et al. generated
perforin-deficient mice, the mice had normal numbers of CD8+ and NK cells, however
several immune functions were compromised, including antiviral and transplantation
antigen-specific CTL activity.219 These mice could not clear a lymphocytic
choriomeningitis virus infection and also had a diminished ability to control the growth
of tumours. However, even in the absence of perforin, there was some lytic activity
which was less effective.
Fas
Apoptosis-mediated cell killing by CTLs is able to explain the ability of CD8+ cells in
perforin-deficient mice to kill target cells. The cell surface receptor, FasR, can lead to
apoptotic cell death.220–222 When FasR- or FasL- mice are generated, they suffer from
similar pathologies of perforin- mice, including autoimmunity and accumulation of large
numbers of lymphocytes. FasL- lymphocytes are able to kill cells, but at a reduced rate of
approximately 10-30% compared to wild type CTLs.220 This residual lysis is probably
due to perforin-mediated killing. An important finding was that perforin- CTLs were
inactive against FasR-deficient target cells, meaning that these are the two pathways
responsible for CTL-mediated cell death. Overall, Lowin concludes that perforin is likely
responsible for approximately two thirds of CTL-mediated killing, while Fas is
responsible for the remainder in vivo.220 One downfall of Fas-mediated killing is that
FasR expression can be different on cells and can be modulated in certain circumstances,
such as when some viruses are able to downregulate FasR expression on cells.220,221
Granzyme
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Perforin only causes membrane damage and is insufficient in explaining DNA
fragmentation and apoptosis shown in CTL target cells.212,223 Therefore it was
hypothesized that another molecule must be responsible for the DNA fragmentation and
apoptosis, once it is released from the CTL and is able to enter the target cell via pores
made by perforin.212,224

1.4.5.3

The T Cell Receptor and Activation Markers

T Cell Receptor
T cell receptors are found on the surfaces of T cells responsible for recognizing antigen
from other cells. They are made up of two polypeptides (α and β) linked by disulfide
bonds. These polypeptides are associated with other invariant CD3 proteins.225–228 The α
and β polypeptide chains are coded by the rearrangement of germline genes; these
random associations allow for the production of thousands of different, mature genes.225
The TCR recognizes antigens when they are bound to an MHC molecule.225
CD69
CD69 is an early membrane receptor, a membrane type II C-type lectin,121 and is
expressed on activated, but not resting, lymphocytes.229 After activation, an early change
that occurs in T cells is the induction of genes encoding cell surface molecules.230 CD69
has been detected on cell surfaces within 1-2 hours after activation.230–232 There are other
activation markers that exist, for example CD25, CD71, and HLA-DR,121,233–235 however
CD69 is very commonly used for T cells because of how quickly it can be found on cell
surfaces. T cells that are stimulated through the TCR (CD3) complex express
CD69,230,232,236–238 therefore mitogens such as PHA and PMA are able to induce the
expression of CD69 in lymphocytes.230,232,238,239 In addition to lymphocytes, CD69 is
expressed on all bone-marrow derived cells except RBCs.229,240 In some instances, CD69
can be expressed on B cells, neutrophils, and freshly isolated monocytes, however the
mechanisms by which CD69 is induced are different from T cells.230

21

1.5 Drugs Commonly Associated with DHRs
A number of drugs are associated with ADRs and DHRs, particularly antibiotics
(especially beta-lactam antibiotics) and anti-convulsants,241,242 as well as NSAIDs (nonsteroidal anti-inflammatory drugs), anti-retrovirals (eg. Abacavir), sulfonamides, and
allopurinol.242 One issue that is currently lacking in the literature is whether different
drugs are linked to DHRs caused by different T cell subsets and whether different DHR
phenotypes are associated with different T cell responses.

1.5.1

Sulfamethoxazole

Sulfamethoxazole (SMX) has been previously associated with DHRs. SMX has been
previously shown to recognize or activate drug-specific T cell clones.55,243 Specifically,
CD4+ and CD8+ T cells have previously been shown to be involved in reactions to
SMX.103
Sulfamethoxazole is typically prescribed with trimethoprim (TMP). Bacteria are obligate
folic acid synthesizers, as opposed to humans who must obtain folic acid through diet.
Both SMX and TMP take advantage of bacteria requiring folic acid to survive by
inhibiting the synthesis of tetrahydrofolic acid, a necessary cofactor for bacterial DNA,
thymidine, and purines.244 Typically, it is prescribed as 20 parts SMX to 1 part
TMP.244,245 This is to provide synergistic antibacterial activity as SMX and TMP target
the folic acid synthesis pathway at different steps, blockading two separate steps prevents
bacterial resistance to either component alone.244,246
The primary route of SMX clearance is via metabolism in the liver by N-acetyltransferase
and N-glucoronyl-transferase; these enzymes lead to the production of non-toxic
metabolites.243,247 CYP-450 also metabolizes a small amount of SMX into hydroxylamine
(SMX-HA) which under physiology conditions is rapidly converted to
nitrososulfonamide (SMX-NO).247,248 SMX-NO is extremely reactive and may be central
to many hypersensitivity reactions.
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1.5.2

Beta-lactam antibiotics

Beta-lactam antibiotics have been previously implicated in T cell-mediated DHRs. It has
been previously shown that CD4+ and CD8+ T cell clones could be activated by
piperacillin in patients with cystic fibrosis and beta-lactam antibiotic hypersensitivity.100
Brander et al. also found a heterogeneous T cell response (of CD4+ and CD8+ T cells) to
penicillin-hypersensitive individuals.249
Beta-lactam antibiotics are widely used for treating bacterial infections in humans, but
can also cause many immune-mediated allergic reactions.250 β-lactam antibiotics inhibit
cell wall synthesis in bacteria by inhibiting transpeptidases, inducing lysis and cell
death.34,251 Bacteria have developed a resistance to beta-lactam antibiotics, making many
drugs ineffective.27,252–254
The basic structure of a penicillin consists of a beta lactam ring, which is condensed to a
thiazolidine ring. At position 6 of the structural backbone, there is an amine-bonded side
chain, which is different depending on the type of penicillin.250 Specifically, amoxicillin
(AMX) is a type of penicillin. It is prescribed either alone or combined to clavulanic acid
(CLV).255
Beta-lactam antibiotics have a ring structure that is responsible for the reactive and
antibiotic activity.256 Once opening, penicillin is rearranged to metabolic by-products,
including penicillic acid, penilloic acid, and penicilloic acid. In addition, 6aminopenicillanic acid may be formed. Beta-lactamases may produce other metabolites,
including penicilloic acid. While not anti-bacterial, these metabolites may form
immunogenic conjugates with proteins.257
Beta-lactams can cause both immediate reactions (typically occurring one hour after drug
intake), and non-immediate reactions.258–260 In terms of the non-immediate DHRs,
maculopapular or morbilliform exanthemas (MPE) are the most common.258,261 It has
been previously shown that AMX may be mediated via the hapten hypothesis.57
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1.6 Clinical Phenotype of DHRs
DHRs can result in a variety of clinical phenotypes, which range in severity. It is not
always known how some individuals experience a more severe rash than another when
taking the same drug. Typically, with delayed type DHRs, exanthemas (widespread rash
that expands quickly) are the most common.262 Several types of lesions also occur,
including pustular, vesicular, and bullar, however maculopapular is the most common.262
Examples of skin reactions that can occur include erythema multiforme, drug reactions
with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson Syndrome and
Toxic Epidermal Necrolysis (SJS/TEN), maculopapular exanthema, and fixed drug
eruption.262,263 Some drugs have been previously associated with different eruptions,
including AMX with bullous skin disease, MPE, and AGEP,49 and NSAIDs, phenytoin,
SMX, and AMX have been observed to cause FDE. Some of these skin reactions have
other accompanied symptoms, such as fever (can be seen with DRESS and SJS/TEN)
headaches, malaise, and fatigue. In some cases, the reaction can induce an autoimmune
response, with one example occurring with prolonged DRESS potentially leading to
drug-induced lupus erythematosus. DHRs can also lead to systemic organ involvement.
Eosinophilia is common, while drug-induced hepatitis,262,264 drug-induced nephritis, and
serum sickness are more rare.262

1.6.1

Skin Rashes

There are many kinds of rashes, and many different diseases or sensitivities can result in
very similar-looking rashes. Allergies can lead to a set of specific types of rashes.
Schlossberg outlines several of these distinctive types of reactions well.265 A rash that is
pruritic is characterized as severe itching.266 Maculopapular rash is a type of eruption
characterized by macules (spots) and papules (bumps). There are several causes of
maculopapular rash, including Lyme disease, Rickettsiosis, rubella, EBV (Epstein-barr
virus), SLE (systemic lupus erythematosus), and allergy, among many more.265 Another
type of rash are vesico-bullous rashes. Vesicles are small blisters, while bullae are large
fluid-filled blisters. There are also several causes of these types of rashes, including
herpes simplex virus, staphylococcemia, HIV (human immunodeficiency virus), and

24

allergy.265 Several cytokines that can be secreted by different T cell subsets have been
described in association with certain skin rashes (described below).

1.6.1.1

Stevens-Johnson Syndrome and Toxic Epidermal
Necrolysis

A very serious type of rash associated with ADRs are seen in Stevens-Johnson Syndrome
and Toxic Epidermal Necrolysis (SJS/TEN), which are acute life-threatening illnesses
that affect the mucous membranes and cause acute epidermal detachment.267–269 SJS and
TEN are two conditions on a spectrum with varying degrees of skin necrosis defined by
the percentage of body surface area (BSA) affected. SJS involves <10% BSA, SJS/TEN
overlap is 10-30% BSA, and TEN is >30% BSA. SJS is fatal in approximately 10% of all
patients, while TEN is fatal in 30-50%. The vast majority (80-95%) of TEN cases are due
to ADRs. Other, less common, causes include recent immunization, acute graft-vs-host
disease, and contrast medium. Early symptoms include fever, malaise, and sore throat
followed by blistering, target lesions, and various degrees of skin detachment.267,270 The
skin lesions typically start on the body’s trunk.267,270,271
Murata et al. determined that increased soluble Fas ligand (sFasL) is associated with SJSTEN, by demonstrating that there was increased sFasL in five of seven cases before
disease onset.272 This difference would set early SJS/TEN apart from other drug
eruptions. The authors note that since sFasL can be due to cell apoptosis in other
diseases, it is important that this test is used only on people experiencing a cutaneous
adverse reaction with high risk for SJS/TEN. Nomura et al. obtained serum samples from
people at the onset of SJS/TEN and compared the cytokine levels to those of people with
other delayed-type ADRs.273 They found that patients with TEN had higher levels of
TNF-α, IL-10 IL-1Rα, IL-6, and GM-CSF. Patients with drug-induced hypersensitivity
syndrome (DIHS) had increased IL-5 when compared to erythema multiforme (EM) and
maculopapular (MP) type rashes. DIHS and TEN had high IL-13 levels, while SJS and
TEN had slightly elevated IFN-γ levels. Pro-inflammatory cytokines and antiinflammatory cytokines are especially increased in TEN. Once SJS/TEN symptoms
improved, IFN-gamma, IL-10, IL-1Rα, and IL-6 levels decreased.273
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CCL27 is production is augmented by TNF-α in keratinocytes by the NFκB pathway.274
Wang et al wanted to know if CCL27 influences the course of SJS/TEN. In serum CCL27
was elevated during SJS/TEN, but low in blister fluid.275 In contrast, they found serum
TNF-α to be low, while blister TNF-α was high. They concluded that while both
contribute to progression of SJS/TEN, their effects were different.275 Granulysin has also
been found to be responsible for widespread keratinocyte death.98,270 Chung and Hung
found granulysin RNA in the blister cells of SJS/TEN, and granulysin was found to be in
greater concentrations than other cytotoxic molecules. Upon injecting the skin of mice
with granulysin, the mice developed an SJS/TEN-like reaction.98,270

1.6.1.2

Acute Generalized Exanthematous Pustulosis

Acute generalized exanthematous pustulosis (AGEP) was previously classified as
psoriasis as it looked similar and was very rare.276 However, Baker and Ryan observed
that some people presenting with AGEP had no previous history of psoriasis, and their
illness was acute, short, and did not recur. They therefore attributed it to an infection or
drugs.277
AGEP is characterized by a pustular rash with fever over 38 °C96,278 on edematous
erythema with a high neutrophil count.96 AGEP will spontaneously resolve within 15
days of onset.96,279
Approximately 90% of all AGEP cases have been associated with drugs, specifically
aminopenicillins.96,279 AGEP has been previously associated with IL-8 secretion by T
cells.96

1.6.1.3

Drug Reaction with Eosinophilia and Systemic Symptoms

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS, also referred to as
DIHS, Drug Induced Hypersensitivity Syndrome) is a drug reaction that has been found
to result after treatment with sulfanimide, phenytoin, dapsone, allopurinol, etc.280–284
DRESS has a late onset (typically 2-8 weeks after use), and also involves fever,
eosinophilia, skin eruption, and lymphocyte activation.280,285 Chen et al. examined
DRESS records from 60 former patients in a Taiwan medical centre.280 They found that
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allopurinol was the most common cause, and the average latency period was 20.7 days.
Some had other symptoms, including exfoliative dermatitis or blistering/purpuric
eruption, in addition to the diffuse exanthematous eruption that all patients had. The
authors also noted some differences in DRESS between patients, therefore questioned
whether it is one disease or a spectrum. DRESS has been previously associated with IL-5
and eotaxin secretion.286,287

1.7 Diagnostic and Predictive Tests for DHRs
1.7.1

In vivo

In vivo tests that currently exist have been used to investigate DHRs are provocation tests
and skin tests. Provocation tests work best for immediate reactions, since delayed
reaction tests are not standardized enough for dose and symptom duration. There is also
some difficulty with defining a positive result. Skin tests have been previously
documented121,259,260,288–290 to have a low sensitivity and are only of utility in immediate
hypersensitivity. They can be performed using a patch, a skin-prick, or an intracutaneous
test.121

1.7.2
1.7.2.1

In vitro
Lymphocyte Toxicity Assay

The lymphocyte toxicity assay (LTA) was developed from assays used to study metabolic
differences between cells of patients and cells of controls. This assay uses isolated
PBMCs to determine if there is greater cell death of drug hypersensitive patient cells
compared to the cells of healthy control when incubated with the drug.291 Dr Rieder’s lab
has had a long experience using these assays as a predictive and mechanistic tool for
studying DHRs.29

1.7.2.2

Lymphocyte Transformation Test

The lymphocyte transformation test (LTT) is a widely used method in studying drug
hypersensitivity.291 This test has been shown to be useful in exploring hypersensitivity
reactions.96,102,103,121,292 The basic principle of this test involves measuring the
incorporation of radio-labelled thymidine (3H-thymidine) in PBMCs to measure cell
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division.243,291,293,294 The result in counts per minute (cpm) is expressed as a stimulation
index (SI). Increased proliferation results in a greater SI value, however high SI values
are not correlated with clinical severity.121

1.7.2.3

Flow Cytometry to Study Activated T Cell Subsets

As previously mentioned, CD69 is a marker present soon after T cell stimulation.
However, there are others including CD25, CD71, and HLA-DR.121,233–235 Two relevant
papers use flow cytometry to detect CD69 upregulation after drug stimulation include one
by Nishio101 and another by Beeler and colleagues.295 Beeler et al. observed that CD69 is
upregulated more in drug-allergic individuals than in non-allergic individuals and suggest
CD69 as a promising tool for detecting drug-reactive T cells in peripheral blood.295 In
addition, CD69 measurement by flow cytometry has been used in other allergies as well,
including delayed hypersensitivity reactions to iodine contrast media.296

1.8 Rationale
My research will attempt to fill the gap that exists in the literature concerning the T cell
phenotypes of drug hypersensitivity reactions. Currently, there are limited numbers of
papers that link T cell subsets with different reactions. There are some papers that link
individual cytokines, chemokines, enzymes, or proteins (see section Immune Mediation
of DHRs) however there is not a full understanding of the physiology of these reactions.
There are several “hypotheses” that attempt to explain the pathophysiology of these
reactions, however there are many unknowns and there is no one mechanism more
supported than the others.
Flow cytometry has been used previously to study these reactions, however it has been
limited in favour of other methods, including ELISA/ELISpot, the LTT, and cloning
drug-specific T cell subsets. Flow cytometry is beneficial because it allows the detection
of multiple fluorochromes bound to multiple proteins on the cell surface, which is
beneficial in staining for both cell type and activation. The overall idea would be to
confirm that the immune cells are dividing in response to drug stimulation, determine
which immune cells are activated during this stimulation, and which cytokines are
secreted as a result. Since certain cytokines are associated with specific T cell subsets,
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these secreted cytokines can be used to determine which T cells could be involved in the
reactions. Consenting participants with confirmed reactions to sulfamethoxazole and
beta-lactam antibiotics will be asked to participate in this study. SMX and AMX were
chosen due how they are both commonly associated with DHRs. The ultimate goal is to
conduct a comprehensive study of the phenotypes of T cell involvement in specific
clinical presentations of hypersensitivity reactions to various medications.

1.8.1

Hypothesis

I hypothesize that differences in activated peripheral T cell subsets and types of
mediators released produce different clinical phenotypes of drug hypersensitivity
reactions to sulphnamides and beta-lactam antibiotics.

1.8.2

Aims

In this study, my aim was to study and characterize lymphocytes isolated from peripheral
blood samples from patients with clinical presentations suggestive of delayed-type drug
hypersensitivity reactions and compare with drug tolerant controls. To do this, I will use
different techniques such as scintillation counting, flow cytometry, and multiplex beadbased assays to measure in vitro PBMC and T cell proliferation. I will use radiolabeled
thymidine incorporation to measure proliferation in response to treatment, flow
cytometry to determine activated T cell subsets, and Luminex, a bead-based detection
assay, to analyze cytokine release of T cell subsets.
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Chapter 2

2

Experimental Design and Methods

This research project is part of a larger drug safety project being conducted in the Rieder
laboratory. The first stage of the project, being performed by another lab member, is to
learn about the symptoms that patients with drug hypersensitivity have by completing a
detailed survey to determine the extent and nature of the reaction. Another component of
the project is to extract DNA from the isolated PBMCs and study markers in each
subgroup of patients exhibiting different clinical presentations of drug hypersensitivity.
My portion of the project was to characterize the T cell phenotypes of the different
clinical presentations of drug hypersensitivity reactions. To date, while there has been
some research into the different types of T cells involved in certain DHRs, much is still
unknown. To do this, I obtained venous blood samples from patients and controls and
isolated and characterized isolated PBMCs/T cells. A methods schematic is detailed in
Figure 2-1. Research ethics had been previously obtained by Dr. Rieder’s laboratory for
this project (REB # 1118833E).

Figure 2-2-1: Schematic of methods used
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2.1 General Methods
2.1.1

PBMC Isolation

We isolated PBMCs from whole blood using density gradient separation. First,
approximately 15 ml of blood was diluted 1:1 in 1× phosphate buffered saline (PBS,
protein-free, pH 7.2, Gibco by Life Technologies, catalogue no. 20012-027). Then, 30 ml
of the blood + PBS 1:1 mixture was carefully layered over 15 ml of Ficoll Histopaque1077 (Sigma, catalogue no. 10771), and centrifuged for 20 minutes (increased to 30
minutes if blood was drawn the day before) at 1500 rpm. The grey PBMC layer was
transferred to new 50ml tubes by serological pipette, and washed twice, each time with a
full tube (50 ml) of PBS and centrifuged at 1600 rpm for 10 minutes. The PBMCs were
diluted to 5 × 106 cells/ml in Roswell Park Memorial Institute (RPMI) medium (+ Lglutamine, 1640 1×, catalogue no. 11875-093) supplemented with 10% human AB serum
(Sigma, catalogue no. H3667) by manual counting with a hemocytometer.

2.1.2

Preparing Universal Mitogen Stimulation Plates

To prepare for stimulation, anti-CD3 antibody (Ultra-LEAF purified antihuman CD3
antibody, clone OKT3, Biolegend, catalogue no. 317325) was coated on the bottom of a
U-bottom 96-well plate. To the required number of labelled wells, 2 µl anti-CD3
antibody (at 1mg/ml) and 98 µl of 1× protein-free PBS are added. The plate was wrapped
in parafilm and left in the fridge (4 °C) overnight. The following day, the plates were
centrifuged at 1600 rpm for 10 minutes and the supernatant decanted before PBMCs or T
cells were added into coated wells.

2.1.3

Assessing Proliferation by Scintillation Counting

For scintillation counting, the stimulants included anti-CD3, the drug the patient was
sensitive to, or culture media (RPMI + 10% human AB serum) as an unstimulated
control. The PBMCs were incubated with the stimulant, drug, or media for 54 hrs and 4
days in an incubator at 37 °C and 5% CO2. Sixteen hours before harvesting the plates, 1
µCi of tritiated thymidine (Thymidine, [methyl-3H], Perkin Elmer, catalogue no.
NET027005MC, lot no. 201510) was diluted in culture media 1:10, then 10 µl of the
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tritiated thymidine/media mixture was added to both stimulated (by anti-CD3 and drug)
and unstimulated PBMCs (alternatively, the 3H-thymidine is diluted 1:25 in media, and
added to all wells with a repeater pipettor if number of wells is very high). The PBMCs
were then washed and harvested using a cell harvester (Tomtec, Hamden, CT), and the
thymidine incorporation is assessed using a MicroBeta counter (Micro Beta Jet, Perkin
Elmer1450 LSC & Luminescence Counter). Proliferation is assessed by calculating the
stimulation index (SI), by subtracting average background counts per minute (cpm) from
the average cpm of each type of sample, then dividing by the average of the unstimulated
wells.

2.1.4
2.1.4.1

Assessing Proliferation of T Cell Subsets by Flow Cytometry
Flow Cytometry Protocol

PBMCs were seeded into a U-bottom 96-well plate, then stimulated in vitro with the drug
the patient had a reaction to (ie. AMX or SMX) at the test concentrations, or stimulated
with anti-CD3 (see § Preparing Universal Mitogen and Stimulation Plates section), a T
cell mitogen, as a controlled comparison. The cells were incubated for 54 hrs in an
incubator at 37 °C and 5% CO2.
The PBMCs were stained with eBioscience Fixable Viability Dye eFluor 506
(ThermoFisher Scientific, catalogue no. 65-0866-14) according to manufacturer’s
instructions to identify dead cells in the sample. The cells were also stained with
allophycocyanin (APC) mouse antihuman CD3 (BD Pharmingen, clone UCHT1,
catalogue no. 561810) to identify all T cells, brilliant violet 421 (BV421) mouse
antihuman CD8 (BD Horizon, clone RPA-T8, catalogue no. 562429) to identify cytotoxic
T cells, phycoerythrin (PE) mouse antihuman CD4 (BD Pharmingen, clone RPA-T4,
catalogue no. 561843) to identify helper T cells, phycoerythrin-cyanine 5 (PE-Cy5)
antihuman CD69 (eBioscience, clone FN50, catalogue no. 25-0699-41), all according to
manufacturer’s instructions, to identify activated T cells. Single stain controls were
performed with Invitrogen UltraComp eBeads (ThermoFisher Scientific, catalogue no.
01-2222-42). All cells were fixed by resuspension in 100 µl of 4% paraformaldehyde
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solution and 200 μl of 1× PBS + 3% FBS (foetal bovine serum) prior to flow cytometry
analysis. Samples were analyzed within 4 days post-fixing.

2.1.4.2

Flow Cytometry Specifications

All flow cytometry experiments were performed at the London Regional Flow Cytometry
Facility at Robarts Research Institute, Western University. The PBMCs were analyzed on
a Becton Dickinson LSR II analysis cytometer (BD Biosciences), using FACSDiVa
software (version 8.0.1). The flow cytometer is equipped with a 50 mW Coherent Cube
402 nm violet diode laser, a 2 mW Coherent Sapphire state 488 nm blue laser, a 50 mW
Coherent Compass 561 nm solid-state yellow-green laser, and a 40 mW Coherent Cube
640 nm red diode laser.
The violet laser trigon was used to detect Brilliant Violet 421 (detector C, with a 450/50
bandpass (bp) filter and no longpass (lp) mirror), and to detect the fixable viability dye
(detector B, 525/50 bp, 505 lp). The yellow-green laser octagon was used to detect PE
(detector E, 582/15 bp), and PE-Cy7 (detector A, 78/60 bp, 755 lp). The red laser trigon
was used to detect APC (detector C, 670/30 bp).

2.1.4.3

FlowJo Gating Procedure

Data was analyzed using FlowJo software (FlowJo, LLC). On FlowJo, the gates were set
using FMO (fluorescence minus one) controls on the fully stained samples. First, forward
scatter area (FSC-A) was gated against the aqua viability dye to gate only live cells. Side
scatter height (SSC-H) was gated against side scatter width (SSC-W), and forward scatter
height against forward scatter width to gate single cells. Then, CD3 APC was compared
against SSC-A to gate CD3+ and CD3- stained cells. Within the CD3- population, CD69
PE-Cy7 was compared against SSC-A to identify with CD3-CD69+ population. Within
the CD3+ lymphocyte population, CD4 PE was compared against SSC-A to determine the
CD4+ population. Within this gate, CD69 was compared against SSC to determine the
CD4+CD69+ population. From the CD3+ population, CD8 was compared against SSC-A
to determine the CD8+ population. Within this population, CD69 was compared against
SSC-A to determine the CD8+CD69+ population.
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2.1.5

Cryopreservation of PBMCs and T Cells

This method has been adapted from the Canadian Healthy Infant Longitudinal
Development (CHILD) Study, from their 8-Year Biological Samples Collection and
Processing SOP, 23 July 2018 edition.297 Once all appropriate experiments were prepared
with the patient PBMCs and T cells, aliquots of cells were frozen under liquid nitrogen
for future analysis.
The 2× freezing medium was prepared by combining 15 ml of heat-inactivated fetal
bovine serum (FBS), 15 ml of RPMI 1640, and 10 ml of dimethyl sulfoxide (DMSO),
aliquoted in 3 ml volumes and remainder stored at -20 °C.
Both T cells and PBMCs are resuspended at 1 × 107 cells/ml in RPMI 1640 + FBS 1:1.
Labelled cryovials were placed on ice, then 500 μl of PBMC or T cell suspension were
added to each tube. Then we added 500 µl of 2× freezing medium to each cryovial while
on ice.
The Mr Frosty (Nalgene, Thermo Scientific, USA) was prepared by removing the insert
and adding 250 ml of isopropanol to the container. The vial holder was replaced into the
container. The isopropanol was changed after every fifth use. The Mr. Frosty was placed
into the fridge at 4 C more than four hours before it is required. The PBMC and T cell
aliquots were placed into the Mr. Frosty and then into the -80 °C freezer for 4 to 24 hours
(typically overnight), and then the samples were placed into the liquid nitrogen long term
storage tank into a known and recorded location.

2.2

Specific Experimental Procedures and Methods

2.2.1

Assessing Highest CD69 Expression on T Cells

I explored the length of the incubation for incubating isolated PBMCs with the culprit
drug or universal mitogen (anti-CD3). This experiment was based off of a study by
Beeler et al.295 The evening before isolating the PBMCs and plating the cells, I coated 21
wells (three wells per timepoint for five timepoints, five FMO wells, one viability dye
compensation control well) of a U-bottom 96-well plate with anti-CD3 and PBS, as
previously described (see § Preparing Universal Mitogen and Stimulation Plates) and
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allowed the plate to rest in the fridge. I started with 15 ml healthy volunteer blood and
LEAF anti-CD3 as the universal mitogen. I did not have access to hypersensitive patient
samples, so a drug stimulant was not used. I isolated the PBMCs from the 15 ml of blood
(as described in § PBMC Isolation), suspended the PBMCs in 10 ml of RPMI with 1´
penicillin/streptomycin and 10% human AB serum, counted the cells in a hemacytometer,
and adjusted the concentration to 5 ´ 106 cells/ml. The plate with anti-CD3 coated wells
was centrifuged at 1600 rpm for 10 minutes, then I decanted the supernatant and added
200 ul of PBMC suspension to 21 coated wells and 12 uncoated wells. Every 18 hours I
harvested three wells of anti-CD3 stimulated and three unstimulated samples for flow
cytometry and stained with Aqua Viability Dye, CD3 APC, CD4 PE, CD8 BV421, and
CD69 PE-Cy7 (as described in § Assessing Proliferation of T Cell Subsets by Flow
Cytometry subsection A, Flow Cytometry Protocol) for a total of five timepoints. After
staining, the PBMCs were suspended in 100 µl 1 × PBS + 3% FBS and 100 µl 4%
paraformaldehyde for flow cytometer acquisition. Single stain compensation controls for
CD3 APC, CD4 PE, CD8 BV421, and CD69 PE-Cy7 were made fresh using comp beads.
In total, 15 stimulated timepoint samples, 15 unstimulated timepoint samples, five FMO
samples, and five single stain compensation controls were analyzed. To analyze the data,
the unstimulated values were subtracted from the stimulated values in an attempt to
normalize.

2.2.2

Testing Healthy Cells with Concentrations of SMX-HA and
SMX Parent Drug

The purpose of this experiment was to determine the magnitude of cell death caused by
different concentrations of either sulfamethoxazole hydroxylamine reactive metabolite
(SMX-HA) or sulfamethoxazole parent drug (SMX). As SMX-HA is more reactive than
SMX and can cause cell death, we used both drugs to determine the best one to use in this
experiment. The evening before the experiment, I coated nine wells of a U-bottom 96well plate with anti-CD3 (see § Preparing Universal Mitogen and Stimulation Plates) for
flow cytometry.
I isolated PBMCs from approximately 15 ml of healthy volunteer blood and suspended
the PBMCs in 10 ml of RPMI 1640 supplemented with 10% human AB serum. Using a
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hemacytometer, the PBMCs were counted and the concentration was adjusted to 5 × 106
cells/ml. The 96-well plate was centrifuged at 1600 rpm for 10 minutes, and the
supernatant decanted. I added 100 µl of healthy PBMCs to each of the anti-CD3 coated
wells and to 21 non-coated wells. Of the nine anti-CD3 coated wells, five of the
stimulated wells were for FMOs, one of the stimulated wells was for the viability dye
single stain control, three stimulated wells were for control wells – to these wells I added
100 µl RPMI 1640 + 10% human AB serum. I also added 100 µl of media to three
unstimulated wells to be stained with the full panel of fluorescent antibodies. For
unstimulated wells, media was added because no drugs were required, but the final
volume required was 200 µl. Sulfamethoxazole parent drug was added to nine
unstimulated wells in 200 µM, 100 µM, and 50 µM concentrations, three wells each.
Sulfamethoxazole hydroxylamine was added to nine unstimulated wells in 100 µM, 50
µM, and 25 µM concentrations, three wells each. The plate was incubated for 54 hrs. The
cells were harvested into flow cytometry tubes, stained with viability dye, CD3 APC,
CD4 PE, CD8 BV421, and CD69 PE-Cy7, acquired on the LSR II flow cytometer with
FACS Diva and analyzed using FlowJo (see § Assessing Proliferation of T Cell Subsets
by Flow Cytometry). Once a concentration of SMX-HA was found to potentially cause
cell death, two more healthy control participants were tested with anti-CD3 and the
concentration previously found to reduce cell viability, to ensure results were consistent.

2.2.3
2.2.3.1

Processing Patient Samples
Recruiting Participants

Subjects were recruited from patients seen at Dr. Rieder’s Drug Safety Clinic at London
Health Science Centre, Victoria Hospital in London, Ontario. Prospective patients were
determined from a database of Dr. Rieder’s DHR patients, on the basis of having
previously been tested by LTA (Lymphocyte Toxicity Assay) for a T-cell mediated drug
hypersensitivity reaction to either sulfamethoxazole or beta-lactam antibiotics. The LTA
testing was either being conducted simultaneously for patients with a high likelihood
based on clinical history, or one to eight years previously. For these participants, blood
was drawn either at Robarts Research Institute, London, Ontario by Dr. Rieder, or at
University Hospital, in London, Ontario by phlebotomy staff. Inclusion criteria were that

36

they had a positive LTA test, or they were in the process of being tested and their clinical
history strongly suggested DHR, and had a recorded rash or skin condition attributed to
drug exposure. Patients who were very likely to have had a DHR based on history alone
who were referred to LTA testing. For these participants, blood was drawn at the same
time as the blood for the LTA testing. I called previous or current patients and asked if
they would be willing to provide a sample for the study, or to add one 1-2 tubes of blood
to their LTA testing. The details of the experiment and their privacy were discussed over
the phone, and they were sent a copy of the Letter of Information (LOI) with the consent
forms either in advance or in person before the appointment. Participants were given a
$10 Tim Horton’s gift card for their time and their sample.

2.2.3.2

Receipt and Preparation of Participant Samples

After patient samples were received, a control sample (~15 ml) of blood was drawn from
a healthy, consenting volunteer. Typically one control was used per one DHR participant.
The control was ideally someone who has taken the drug the patient participant has a
hypersensitivity to but did not have an adverse response, or someone who has served as a
control in previous LTA tests but consistently tests negatively. One control sample and
one patient sample were analyzed at the same time. Depending on availability of samples,
the samples were processed and PBMCs were isolated either the same day or the next day
(see § PBMC Isolation). If PBMCs were isolated the day after blood was collected, an
extra 10 minutes was added to the centrifugation at the Ficoll separation step for those
samples only. PBMCs were re-suspended after isolation to 5 × 106 cells/ml in RPMI +
10% human AB serum. If testing only one drug, 15 ml was prepared, or 20ml for two
drugs, to accommodate additional wells.

2.2.3.3

Preparing SMX and AMX to study Activation

To stimulate PBMCs, four different concentrations were made from analytical grade
powder for each drug, AMX and SMX. Two serial dilution charts (see Figure 2-2 and
Figure 2-3) were used for each patient to make the appropriate dilutions. Drugs were
diluted 1:1 with 100 µL of PBMC suspension to achieve final concentrations of AMX
1000 µM, 500 µM, 100 µM, and 10 µM; SMX 800 µM, 400 µM, 200 µM, and 100 µM.
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All drug preparations were made fresh the day of plating, and either used immediately or
kept in the dark until required (usually only maximum of 1 hr).

Figure 2-2: Serial dilution chart for amoxicillin
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Figure 2-3: Serial dilution chart for sulfamethoxazole

2.2.3.4

Assessing Proliferation by Scintillation Counting

The evening before the PBMCs were plated onto 96-well plates, I made the appropriate
number of anti-CD3 coated plates. Which plates were made depended on which
experiments would be conducted the next day – this was important because cell
harvesting and scintillation counting for proliferation testing could not be performed on a
weekend due to equipment availability, so the 54 hrs and 4 days scintillation counting
plates were coated strategically to avoid this. For each control and participant plate at
both time points, I coated four wells. The following day, 100 ul patient and control
PBMCs at 5 × 106 cells/ml in RPMI + 10% human AB serum were plated with either 100
ul of media (RPMI + 10% human AB serum as negative control), anti-CD3 with added
media to bring volume up to 200 µl, or the 100 µl of the four different concentrations of
the appropriate drug. Four wells of each condition were plated. At 16 hours before
harvesting, 1 µCi of 3H-thymidine was added to each well (see § Assessing Proliferation
by Scintillation Counting for details). See Figure 2-4 for a sample plate layout.
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Figure 2-4: Sample scintillation counting plate layout
If two drugs were plated, the wells occupied rows A-H columns 8-11. One plate is made
for control PBMCs, a second plate is made for patient PBMCs, and two plates are
processed for each 54 hrs and 4 days incubation period.

2.2.3.5

Flow Cytometry for Activated CD4 and CD8 T Cells

The flow cytometry plate cells were harvested into flow cytometry tubes using a plastic
transfer pipette, and PBS to rinse the wells to ensure all cells were transferred into the
tubes. The cells were washed with PBS and centrifuged at 1600 rpm for 10 minutes. The
supernatant was removed by pipette and the cell pellet resuspended in 1 ml of PBS. To all
tubes except the viability dye FMO, I added 1 μl of viability dye. The anti-CD3
stimulated PBMCs were stained with one test each of CD3 APC, CD4 PE, CD8 BV421,
and CD69 PE-Cy7 (see § Assessing Proliferation of T Cell Subsets by Flow Cytometry
subsection A, Flow Cytometry Protocol, for details) while the FMO tubes were stained
appropriately (see Figure 2-5 for a sample flow cytometry staining panel for patient
samples). PBMCs were washed twice with 1 × PBS + 3% FBS, and resuspended in 100
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ul 4% paraformaldehyde, to fix the cells, and 200 µl of 1× PBS + 3% FBS. The
experiment was acquired on the LSR II as soon as possible after staining (within 2-3
days, depending on availability of the cytometer for a 3-hour time slot).

Figure 2-5: Sample flow cytometry staining panel for patient and control samples

2.2.3.6

Assessing Cytokine Release

Isolated PBMCs and T cells from both control and patient samples were stimulated with
anti-CD3, the drug concentrations, and culture media (unstimulated) in duplicate. The
evening before plating, two anti-CD3 plates are prepared (see § Preparing Universal
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Mitogen Stimulation Plates). T cells were only isolated and plated if there were enough
cells remaining from the patient and control samples to justify isolating them without
compromising cell numbers for other experiments. The plates were divided into two (one
half for PBMCs, one half for T cells), and two wells are coated in each half (4 wells total
per plate). PBMCs were plated in duplicate at 5 × 106 cells/ml in RPMI + 10% human
AB serum with either media (control), anti-CD3, or the four concentrations of either drug
(AMX or SMX). After a 3-day incubation at 37 °C and 5% CO2, the supernatant was
removed from samples, stored in labelled Eppendorf 2 ml tubes, and frozen at -80 C until
analysis could be completed.
Stimulated DHS and control participant PBMCs were subjected to Luminex analysis.
Since the AMX data was more promising, only AMX participants and controls were
included in the Luminex analysis. Control and DHR 006 participants were not analyzed
due to heavy RBC contamination in DHS006 samples.
A custom Luminex kit was ordered from Bio-Rad (Hercules, CA), specific for analytes
IFN-y, IL-9, IL-22, IL-17A, and IL-13 (PO # 0222850). The analysis was performed
according to manufacturer’s instructions. The beads were diluted as instructed by the
manufacturer. Since it was a custom kit, some beads were 2× as concentrated as others,
so they were diluted appropriately. A plate layout was generated (see Figure 2-6), with all
blanks, standards, and samples analyzed in duplicate. A standard curve was generated for
the beads. Bio-Rad suggests neat to 1:10 dilution, but since some of the standards had
such a high starting concentration, we chose neat to 1:12 dilution to accommodate this, as
well as to fill up the plate.
Frozen supernatants were thawed over ice and centrifuged for 3 minutes at 12000 rpm to
pellet any debris. Since the supernatants were composed of culture media (with added
protein), no BSA was added to the samples. Then 50 µl of the diluted beads were added
to each well and washed two times with wash buffer and the magnetic plate. Then, 50 µl
of samples, standards, and blank were added to each well, covered, and incubated with
shaking for 1 hr. With 10 mins remaining in the incubation, the antibodies were diluted to
1× according to instructions. The plate was washed three times with wash buffer and the
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magnetic plate, then 25 µl of detection antibodies was added to each well. The plate was
covered and incubated with shaking for 30 mins. With 10 mins remaining in the
incubation, the streptavidin-PE (SA-PE) was prepared. The plate was washed three times
with wash buffer and the magnetic plate, then 50 µl of diluted SA-PE was added to each
well. The plate was covered and incubated for 10 mins. A final round of three washes
was performed, and each well was resuspended in 125 µl of assay buffer. The plate was
covered and placed on the shaker until analysis.
A Bio-Plex 200 readout system (Bio-Rad) was used to analyze the cytokines. This system
uses Luminex ® xMAP fluorescent bead-based technology (Luminex Corporation,
Austin, TX). Cytokine levels (pg/ml) were automatically calculated from standard curves,
generated by the Bio-Plex Manager software (v. 6.1, Bio-Rad, Hercules, CA).

Figure 2-6: Luminex sample plate layout
S1-S12: standard bead dilutions, D4-D8: DHS participant, C4-C8: control participant. All
samples were supernatants of PBMCs incubated with AMX.
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2.3 Statistical Methods
An ANOVA can be used to test three or more groups without inflating the alpha value,
which would be the case with multiple comparisons.298 Repeated measures ANOVA
(rANOVA) was used to perform many of the statistical analyses as the same participants
were tested repeatedly across the dependent variable. This is beneficial as it reduces the
error.
However, one important aspect of rANOVA is sphericity. When sphericity is violated,
the test becomes too liberal (increases Type I error rate) and therefore might indicate a
significant result when it should actually be not significant. As a result, there are some
tests that correct the rANOVA by increasing p to make the test more conservative. We
chose to analyze sphericity-violated rANOVAs with the Greenhouse-Geisser correction.
A previous analysis by Muller and Barton (1989) supports the use of the GreenhouseGeisser correction (over Huynh-Feldt) due to acceptably controlling for Type I error
while also maximizing power.299
While we did use statistical methods when appropriate, it is important to note that the N
of the study was relatively small for certain tests, it would be prudent to increase the
number of participants in the study to increase the power.
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3

Experimental Set 1

It has been previously shown that T cells appear to be key mediators of DHRs.53,54,96–104
While it is not fully understood how they are involved, it is thought that they, as well as
their mediators, are primarily responsible for the immunological pathogenesis of these
reactions. In addition, CD69 has been previously shown to be an activation marker that is
expressed on the T cell surface rapidly after activation.295 However, CD69 does not
remain on the cell surface indefinitely, and its quantity can change after activation. For
our own purposes, it was important to do our own tests to observe what methods would
work for us. This includes which metabolites to use, length of incubation time, percent of
CD69 expression.

3.1 Using SMX Yields more Live Cells than SMX-HA
In addition to sulfamethoxazole (SMX) parent drug, there are two intermediates that can
also cause a reaction, however they differed in their toxicity. To decide which form of
SMX we would use, I tested concentrations of SMX and sulfamethoxazole
hydroxylamine (SMX-HA). PBMCs from one volunteer donor were incubated with
culture media (unstimulated), 500µM, 100µM, and 200µM SMX, and 25µM, 50µM, and
100µM SMX-HA, and analyzed by flow cytometry for the percentage of live cells
remaining after incubation (Figure 3-1).
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Figure 3-1: Percentage of live cells after PBMCs from a healthy control were
incubated with either culture media, SMX, or SMX-HA for 54 hours
Concentrations of 50µM, 100µM, and 200µM SMX; 25µM, 50µM, and 100µM SMXHA for 54 hrs. N = 1.
Without statistical analysis, given the small sample size (N=1), there do not seem to be
any differences between the SMX-stimulated samples. However, there was a decrease in
cell viability when the PBMCs were incubated with 100µM SMX-HA. To confirm, this
concentration was repeated with two additional healthy controls, increasing the sample
size to 3 (Figure 3-2). A Student’s t test confirmed that 100µM SMX-HA significantly
reduces cell viability (p = 0.0017).
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Figure 3-2: Percentage of live cells remaining after PBMCs from three controls were
incubated with 100uM SMX-HA for 54 hrs
The PBMCs incubated with 100µM SMX-HA have a significantly lower number of live
cells remaining after incubation compared with unstimulated PBMCs with media alone
(student’s t test, one-way, p = 0.0017). N = 3, ± SEM.

3.2 Length of Incubation affects Viability of PBMCs
To determine the best length of time for incubating PBMCs with a stimulant, PBMCs
were incubated with plate-bound anti-CD3 for five intervals of 18 hours, in an
experiment similar to Beeler et al.295 First, the percent of live PBMCs remaining after
incubation was analyzed every 18 hours by flow cytometry (Figure 3-3). There was a
gradual decrease in viability as the timepoints increased. At 90 hrs, viability decreased to
an average of approximately 50% viability. Our chosen timepoint of 54 hrs did not differ
significantly from 18hrs.
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Figure 3-3: The percent of live cells remaining after PBMCs were incubated with
plate-bound anti-CD3 at 18 hr intervals for 90 hrs
A repeated measures ANOVA was conducted to determine if any time intervals were
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was
violated, therefore the Greenhouse-Geisser correction was used. There was a significant
effect of time on number of live PBMCs remaining. F(1.164, 2.328) = 25.351, p = 0.027.
N = 3, ± SEM.

3.3 Percent of T Cells expressing CD69 during Incubation
PBMCs were also analyzed for percent CD69 expression and MFI of CD69 across CD3+,
CD3+CD4+, and CD3+CD8+ cell types. Unstimulated percent of CD69 expression
values were subtracted from anti-CD3 stimulated values. With the CD3+ percent CD69
and MFI (Figures 3-4 and 3-5), there were no significant timepoints, however the overall
appearance of the data can be described. With both the percent CD69 and the MFI of
CD69, 18, 54, and 72 hr timepoints appeared to be the highest. With CD3+CD4+ percent
CD69 and MFI (Figures 3-6 and 3-7), the trends were different, but again not significant.
With the percent CD69 (Figure 3-6), there seemed to be an overall decrease in percent
CD69 expression from the 18 hr to the 90 hr timepoint. With the MFI of CD69 (Figure 37), the 18 hr, 54 hr, and 72 hr timepoints were the highest, however the values were more
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variable. With CD3+CD8+ percent CD69 and MFI (Figures 3-8 and 3-9), while also
providing no significant timepoints.
While there were no significant differences between timepoints (that either caused a
significantly higher or lower cell viability), the timepoint 54 hrs was chosen for the
participant experiments.
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Figure 3-4: Percentage of CD3+ T cells expressing CD69, assessed by flow
cytometry, after PBMCs from three healthy control participants were incubated
with anti-CD3 for 90 hrs for intervals of 18 hrs
A repeated measures ANOVA was conducted to determine if any time intervals were
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was
violated, therefore the Greenhouse-Geisser correction was used. There was no significant
effect of time on percent CD69 expression on CD3+ T cells. F(1.041, 2.081) = 1.494, p =
0.346. N = 3, ± SEM.
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Figure 3-5: MFI of CD69 expressing CD3+ T cells, assessed by flow cytometry,
after PBMCs from three control participants were incubated with anti-CD3 for 90
hrs for intervals of 18 hrs
A repeated measures ANOVA was conducted to determine if any time intervals were
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was
violated, therefore the Greenhouse-Geisser correction was used. There was no significant
effect of time on the MFI of CD69 expression on CD3+ T cells. F(1.072, 2.145) = 0.495,
p = 0.563. N = 3, ± SEM.
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Figure 3-6: Percentage of CD3+CD4+ T cells expressing CD69, assessed by flow
cytometry, after PBMCs from three healthy control participants were incubated
with anti-CD3 for 90 hrs for intervals of 18 hrs
A repeated measures ANOVA was conducted to determine if any time intervals were
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was
violated, therefore the Greenhouse-Geisser correction was used. There was no significant
effect of time on % CD69 expression on CD3+CD4+ T cells. F(1.087, 2.173) = 3.660, p =
0.188. N = 3, ± SEM.
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Figure 3-7: The MFI of CD69 expressing CD3+CD4+ T cells, assessed by flow
cytometry, after PBMCs from three healthy control participants were incubated
with anti-CD3 for 90 hrs for intervals of 18 hrs
A repeated measures ANOVA was conducted to determine if any time intervals were
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was
violated, therefore the Greenhouse-Geisser correction was used. There was no significant
effect of time on the MFI of CD69 expression on CD3+CD4+ T cells. F(1.072, 2.144) =
0.362, p = 0.619. N = 3, ± SEM.
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Figure 3-8: Percentage of CD3+CD8+ T cells expressing CD69, assessed by flow
cytometry, after PBMCs were incubated with anti-CD3 for 90 hrs for intervals of 18
hrs
A repeated measures ANOVA was conducted to determine if any time intervals were
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was
violated, therefore the Greenhouse-Geisser correction was used. There was no significant
effect of time on percent CD69 expression on CD3+CD8+ T cells. F(1.689, 3.378) =
1.735, p = 0.296. N = 3, ± SEM.
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Figure 3-9: The MFI of CD69 expressing CD3+CD8+ T cells, assessed by flow
cytometry, after PBMCs from three control participants were incubated with antiCD3 for 90 hrs for intervals of 18 hrs
A repeated measures ANOVA was conducted to determine if any time intervals were
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was
violated, therefore the Greenhouse-Geisser correction was used. There was no significant
effect of time on the MFI of CD69 expression on CD3+CD8+ T cells. F(1.216, 2.432) =
0.744, p = 0.493s. N = 3, ± SEM.
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Experimental Set 2

Both sulfamethoxazole (SMX) and beta-lactam antibiotics (for example, penicillin) have
been previously shown to elicit DHRs.137,258,259,261 In addition, both are commonly
prescribed antibiotics. The lymphocyte transformation test (LTT) is an effective
diagnostic test for delayed type DHRs.96,102,103,121,292 Flow cytometry has been previously
used to detect CD69 upregulation after drug stimulation.101,295,296 While its use in delayed
type DHRs has been limited, it is a promising way to detect cellular response using
surface proteins. In addition, differences in cytokine secretion, which can be analyzed in
several different ways, are an effective way to study DHRs.137,186,300 The goal was to
determine if there were patterns among the clinical presentations of people previously
diagnosed with DHRs to SMX and AMX.

4.1 Description of Participant Population
The mean age of DHR participants (Table 4-1) was 50.5 years, with a standard deviation
of approximately 19.1 years, and the ratio of female to male participants was 7:1. The
mean age of the control participants (Table 4-2) was 31.125 years, with a standard
deviation of 13.3, and a female to male participant ratio of 4:4. Student’s t-test confirmed
that there was a significant difference in average age between the two participant
populations (Student’s t-test, one-tailed, p = 0.017). All control AMX participants had
previously taken the drug, while the control participants either had never taken
sulfamethoxazole or had no recollection.
It is important to note that within the SMX participants, of the four oldest participants,
three were DHS participants. Within the AMX participants, of the four oldest, again three
were DHS.
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Table 4-1: List of participants with drug allergies that took part in the study,
recruited from Dr. Michael Rieder’s drug allergy clinic at London Health Sciences
Centre, in London, Ontario, Canada
Participant
identifier

Age as of
collection date

Listed Drug
sex
tested

History/symptoms with drug

DHS001

52 F

SMX

Rash (unspecified)

DHS002

72 F

SMX

No recollection

DHS003

48 F

SMX

Oral blistering (SJS?)

DHS004

51 F

AMX

Serum-sickness like

DHS005

22 F

AMX

Morbilliform rash

DHS006

63 M

AMX

SJS

DHS007

24 F

AMX

Rash (unspecified)

DHS008

68 F

AMX and
SMX

Pruritic rash, requiring
hospitalization

Table 4-2: List of control participants that participated in the study, recruited from
Western University, in London, Ontario, Canada
Participant
identifier

Age as of
collection date

Listed
sex

Drug
tested

History/symptoms with drug

C001

27 F

SMX

No recollection

C002

21 F

SMX

Never taken sulfa

C003

60 F

SMX

Never taken sulfa

C004

41 M

AMX

Taken before, no adverse
reactions

C005

23 M

AMX

Taken before, no adverse
reactions
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C006

24 F

AMX

Taken before, no adverse
reactions

C007

24 M

AMX

Taken before, no adverse
reactions

C008

26 M

AMX and
SMX

Taken AMX before, unsure
about SMX

4.2 Scintillation Counting Results
Control and SMX/AMX participant PBMCs were also incubated with the drug and 3Hthymidine to determine if the drug stimulated DHS participant PBMCs, resulting in the
proliferation of cells and a high stimulation index (SI). SI is a ratio of unstimulated
PBMCs to drug stimulated PBMCs. Typically, an SI of 2 is required to say that the
PBMCs are responding to the drug in vitro.

4.2.1

Scintillation Counting Results from SMX-Hypersensitive
Participants

When control and DHR participant PBMCs were incubated with SMX for 54 hrs, there
was no significant change in SI (Figure 4-1), and there was no trend observed for either
control or DHR participants (ie. no overall increase or decrease). There were no SIs at or
greater than 2, therefore none shows a positive proliferative response to the drug
treatment.
Control and DHR participant PBMCs were also incubated with SMX for 4 days (Figure
4-2). Again, none of the concentrations of SMX were found to be significant. None of the
participants had a SI greater than 1.2.
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Figure 4-1: SI of control and DHS participants after incubation with SMX for 54
hrs
A repeated measures ANOVA was conducted to determine if the concentration of SMX
had an effect on the proliferation of control and DHS PBMCs. Mauchly’s test of
sphericity was not significant (p = 0.263), therefore the assumption was met and a
Greenhouse-Geisser correction was not used. F(4, 24) = 0.443, p = 0.776. N(control) = 4
and N(DHR) = 4, ± SEM.
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Figure 4-2: SI of control and DHS participants after incubation with SMX for 4
days
A repeated measures ANOVA was conducted to determine if the concentration of SMX
had an effect on the proliferation of control and DHS PBMCs. Mauchly’s test of
sphericity was not significant (p = 0.468), therefore the assumption was met and a
Greenhouse-Geisser correction was not used. F(4, 24) = 3.234, p = 0.029. N(control) = 4
and N(DHR) = 4, ± SEM.

4.2.2

Scintillation Counting Results from AMX-Hypersensitive
Participants

In addition to SMX, AMX participants were also recruited. Participant PBMCs were
incubated with AMX for 54 hrs (Figure 4-3). No participant had a SI greater than 1.2, and
no significant differences between control and DHR participant or unstimulated and drug
concentration were found. When incubated with AMX for four days, there were no
significant differences between control and DHR participant, or between unstimulated
and drug stimulated (Figure 4-4).
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Figure 4-3: SI of control and DHS participants after incubation with AMX for 54
hrs
A repeated measures ANOVA was conducted to determine if the concentration of SMX
had an effect on the proliferation of control and DHS PBMCs. Mauchly’s test of
sphericity was not significant (p = 0.606), therefore the assumption was met and a
Greenhouse-Geisser correction was not used. F(4, 32) = 1.457, p = 0.238. N(control) = 4
and N(DHR) = 4, ± SEM.
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Figure 4-4: SI of control and DHS participants after incubation with AMX for 4
days
A repeated measures ANOVA was conducted to determine if the concentration of SMX
had an effect on the proliferation of control and DHS PBMCs. Mauchly’s test of
sphericity was not significant (p = 0.681), therefore the assumption was met and a
Greenhouse-Geisser correction was not used. F(4, 32) = 0.296, p = 0.878. N(control) = 4
and N(DHR) = 4, ± SEM.

4.3 Flow Cytometry Results
4.3.1

Representative Flow Cytometry Charts

To gate the PBMCs analyzed by flow cytometry, first live cells were gated according to
viability dye (Figure 4-5-i). Then, single cells were gated until the cells could be gated as
CD3+ and CD3- (Figure 4-5-v). CD3+ cells were further gated for being CD69+ (4-5-vi),
CD4+ (4-5-vii), and CD8+ (4-5-viii). Both CD3+CD4+ and CD3+CD8+ T cells were gated
for CD69 (4-5-x and 4-5-xi, respectively). In addition, CD3- cells were also examined for
CD69 expression (Figure 4-5-ix). Just as CD69 expression can be represented as dot
plots, it can also be presented as MFI of CD69 histograms (Figure 4-10). All gating and
analyses were performed on FlowJo. All participants (both control and DHR) were gated
in the same way.
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Figure 4-5: Representative flow cytometry dot plot and gating procedure

Figure 4-6: Representative MFI of CD69 expression histogram
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4.3.2

Participants were Eliminated According to Cell Viability and
Percent of CD3+ Cells

The percent of live cells remaining after incubation with both SMX and AMX was
assessed for each control and DHR participant. In addition to CD69 expression, cell
viability and the percent of T cells (CD3+) of total cells acquired were looked at. Cell
viability was measured using a viability stain that enters cells with compromised cellular
membranes, and binds to proteins within the cell. Cells positively stained with the dye
can be gated as dying or dead cells on the flow cytometer and can be excluded from
subsequent analysis.
Four DHR participants and three control participants were tested in culture media
(unstimulated), four concentrations of SMX (100, 200, 400, 800 µM), and anti-CD3 (data
not shown for anti-CD3). Within the DHR participants (DHS001-003, 008) tested (see
Figure 4-7), two participants had cell viability under 50% across all conditions (DHS001,
average cell viability of 38.12%, and 002, average cell viability of 9.18%). Two SMX
concentrations could not be acquired in DHS008 (100µM and 200µM). Within the three
control participants (Control001-003) tested (see Figure 4-8), Control002 had less than
50% viability across all conditions (average cell viability of 14.43%). In Control001, only
the SMX 800µM condition had viability at slightly under 50%, all other conditioners
were higher. Because of these low viabilities, DHS001, DHS002, and Control002 were
excluded from subsequent analyses.
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Figure 4-7: Percent of live PBMCs analyzed from total number of DHR participant
PBMCs after incubation with concentrations of SMX, acquired by flow cytometry,
as a measure of cell viability
PBMCs were incubated with culture media (unstimulated), anti-CD3, and SMX at
concentrations 100µM, 200µM, 400µM, and 800µM.
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Figure 4-8: Percent of live PBMCs analyzed from total number of control
participant PBMCs after incubation with concentrations of SMX, acquired by flow
cytometry, as a measure of cell viability
PBMCs were incubated with culture media (unstimulated), anti-CD3, and SMX at
concentrations 100µM, 200µM, 400µM, and 800µM.
In addition to SMX, five DHR participants and four control participants were tested with
culture media (unstimulated), four concentrations of AMX (10µM, 100µM, 500µM,
1000µM), and anti-CD3. All participants, both DHR (see Figure 4-9) and control (see
Figure 4-10), had cell viability greater than 50% (lowest viability was 70.77% and
greatest was 90.39%), therefore all were included in subsequent analyses.

65

% live cells from total acquired

100
90
80
70
60
50
40
30
20
10
0
Unstimulated
DHS004

10uM AMX
DHS005

100uM AMX
DHS006

500uM AMX
DHS007

1000uM AMX
DHS008

Figure 4-9: Percent of live PBMCs analyzed from total number of DHR participant
PBMCs after incubation with AMX, acquired by flow cytometry, as a measure of
cell viability
PBMCs were incubated with culture media (unstimulated), anti-CD3, and AMX at
concentrations 10µM, 100µM, 500µM, and 1000µM.
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Figure 4-10: Percent of live PBMCs analyzed from total number of control
participant PBMCs after incubation with AMX, acquired by flow cytometry, as a
measure of cell viability
PBMCs were incubated with culture media (unstimulated), anti-CD3, and AMX at
concentrations 10µM, 100µM, 500µM, and 1000µM.
The percent of CD3+ T cells was also analyzed by flow cytometry. Within the SMX DHR
participants (see Figure 4-11), the percentages of CD3+ at each concentration were very
different. DHS001 and DHS002 both had low percent of CD3+ T cells (averages of
14.85% and 0.54%, respectively). In the SMX control participants (see Figure 4-12),
Control002 also had a very low percentage of CD3+ T cells acquired (approximately
1.31% across all conditions).
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Figure 4-11: Percent of CD3+ cells analyzed from total number of DHR participant
PBMCs after incubation with SMX, acquired by flow cytometry
PBMCs were incubated with culture media (unstimulated), anti-CD3, and SMX at
concentrations 100µM, 200µM, 400µM, and 800µM.
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Figure 4-12: Percent of CD3+ cells analyzed from total number of control
participant PBMCs after incubation with SMX, acquired by flow cytometry
PBMCs were incubated with culture media (unstimulated), anti-CD3, and SMX at
concentrations 100µM, 200µM, 400µM, and 800µM.
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As for AMX control (Figure 4-13) and DHR participants (Figure 4-14), most percentages
of CD3+ T cells were high, except for DHS006, which was very low (average of
approximately 0.74% across all conditions). Because of this, DHS006 was removed from
all subsequent analyses.
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Figure 4-13: Percent of CD3+ cells analyzed from total number of DHR participant
PBMCs after incubation with AMX, acquired by flow cytometry
PBMCs were incubated with culture media (unstimulated), anti-CD3, and AMX at
concentrations 10µM, 100µM, 500µM, and 1000µM.

69

100

% CD3 cells of total acquired

90
80
70
60
50
40
30
20
10
0
Unstimulated
Control004

10uM AMX
Control005

100uM AMX

500uM AMX

Control006

1000uM AMX
Control007

Figure 4-14: Percent of CD3+ cells analyzed from total number of control
participant PBMCs after incubation with AMX, acquired by flow cytometry
PBMCs were incubated with culture media (unstimulated), anti-CD3, and AMX at
concentrations 10µM, 100µM, 500µM, and 1000µM.

4.3.3

Control and DHR Participant Results with SMX Incubation

Two control and DHR participant results were analyzed after participants had been
removed, and graphed according to percent of CD69 expression and MFI of CD69 across
CD3+, CD3+CD4+, CD3+CD8+, and CD3- cell types as a result of incubation with
increasing concentrations of SMX (Figures 4-15 to 4-30).
With CD3+ cells (Figure 4-15 to 4-18), there was no increase in proliferation across
concentrations, and no detectable difference between control and DHR participants. With
percent CD69 (Figure 4-15), the only participant that had some increase beyond
unstimulated was DHS008 at 800µM SMX. However, when averaged with DHS003
(Figure 4-16), the average did not appear to be different from unstimulated. As for the
individual MFI values (Figure 4-17), all values of control and DHR participant were at or
below that of unstimulated regardless of concentration, which is also reflected in the
averaged values (Figure 4-18).

70

It is important to note that as sample size of SMX participants is small, no statistics were
calculated.
With helper (CD3+CD4+) T cells, similarly to CD3+, there were no noticeable increases.
With percent of CD69 expression (Figure 4-19 and 4-20), all normalized values were
below normalized unstimulated levels. Only DHS008 had an increase between 400µM
and 800µM SMX, however both values were not greater than unstimulated. MFI values
were also lower than unstimulated for all concentrations (Figure 4-21 and 4-22).
Control001 showed an odd increase compared to unstimulated in MFI with 100µM SMX,
but was below unstimulated for all other concentrations (seen in Figure 4-21).
As for CD3+CD8+, overall there were no noticeable differences between the
concentrations of SMX. For percent CD69 (Figure 4-23), again DHS008 had a slight
increase between 400uM and 800uM SMX, but not greater than unstimulated.
Control001 had a slight increase over unstimulated for 100µM and 200µM SMX, but
returned to at or below unstimulated in the higher concentrations. On average (Figure 424), no concentrations showed an effect. With MFI (Figures 4-25 and 4-26), Control001,
003 and DHS003 all had similar values, with none of the MFI values greater than
unstimulated, however DHS008 MFI values at 400 and 800µM were very close to 0
when normalized to unstimulated (Figure 4-25). On average, no overall differences were
seen between the groups.
Similar patterns were seen again with CD3- cell types (Figures 4-27 to 4-30). With
percent CD69 (Figures 4-27 and 4-28), DHS008 showed again an increase between
400µM and 800µM, which was slightly above unstimulated. Control001 showed an
increase above normalized unstimulated for all concentrations, while Control003 and
DHS003 values were all below normalized unstimulated. Overall, none of the average
values differed from unstimulated (Figure 4-28). With MFI of CD69, Control001,
Control003, DHS003 all were very similar to unstimulated values across all
concentrations. Only DHS008 showed a low MFI at 400µM and 800µM concentrations.
Overall the MFI of control values did not differ from unstimulated (Figure 4-29 and 430), with DHS only slightly lower due to DHS008.
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Figure 4-15: Percent of CD3+ T cells expressing CD69 in individual control and
DHS participant PBMCs incubated with SMX

CD3 percent CD69 normalized to
unstimulated

200
180
160
140
120
100
80
60
40
20
0
Unstimulated

100uM SMX
Control average

200uM SMX

400uM SMX

800uM SMX

DHS average

Figure 4-16: Average percent of CD3+ T cells expressing CD69 normalized to
unstimulated control, as a result of control and DHS participant PBMCs incubated
with culture media (unstimulated control) and four concentrations of SMX
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Figure 4-17: MFI of CD3+ T cells expressing CD69 in individual control and DHS
participant PBMCs incubated with SMX
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Figure 4-18: Average MFI of CD69 on CD3+ T cells normalized to unstimulated
control, as a result of control and DHS participant PBMCs incubated with culture
media (unstimulated control) and four concentrations of SMX
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Figure 4-19: Percent of CD3+CD4+ T cells expressing CD69 in individual control
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Figure 4-20: Average percent of CD3+CD4+ T cells expressing CD69 normalized to
unstimulated control, as a result of control and DHS participant PBMCs incubated
with culture media (unstimulated control) and four concentrations of SMX
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Figure 4-21: MFI of CD3+CD4+ T cells expressing CD69 in individual control and
DHS participant PBMCs incubated with SMX
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Figure 4-22: Average MFI of CD69 on CD3+CD4+ T cells normalized to
unstimulated control, as a result of control and DHS participant PBMCs incubated
with culture media (unstimulated control) and four concentrations of SMX
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Figure 4-23: Percent of CD3+CD8+ T cells expressing CD69 in individual control
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Figure 4-24: Average percent of CD3+CD8+ T cells expressing CD69 normalized to
unstimulated control, as a result of control and DHS participant PBMCs incubated
with culture media (unstimulated control) and four concentrations of SMX
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Figure 4-25: MFI of CD3+CD8+ T cells expressing CD69 in individual control and
DHS participant PBMCs incubated with SMX
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Figure 4-26: Average MFI of CD69 on CD3+CD8+ T cells normalized to
unstimulated control, as a result of control and DHS participant PBMCs incubated
with culture media (unstimulated control) and four concentrations of SMX
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Figure 4-27: Percent of CD3- PBMCs expressing CD69 in individual control and
DHS participant PBMCs incubated with SMX
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Figure 4-28: Average percent of CD3- PBMCs expressing CD69 normalized to
unstimulated control, as a result of control and DHS participant PBMCs incubated
with culture media (unstimulated control) and four concentrations of SMX
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Figure 4-29: MFI of CD3- PBMCs expressing CD69 in individual control and DHS
participant PBMCs incubated with SMX
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Figure 4-30: Average MFI of CD69 on CD3- PBMCs normalized to unstimulated
control, as a result of control and DHS participant PBMCs incubated with culture
media (unstimulated control) and four concentrations of SMX
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4.3.4

Control and DHR Participant Results with AMX Incubation

A total of four control participants and four DHR participants for AMX were recruited
for this study, which allowed statistical analyses to be performed, unlike with SMX.
With CD3+ percent CD69 (Figure 4-31), Control004 was similar or lower to unstimulated
across all concentrations, Control005 was highest at 10µM AMX but decreased to
unstimulated levels at 1000µM. Control006 was similar to unstimulated but lowered a lot
by 1000µM, and Control007 was lower than unstimulated through 500µM, but increased
slightly past unstimulated at 1000µM. DHS004 was mostly similar to unstimulated
except at 100µM AMX, and DHS005, while initially lower at than unstimulated at 10µM,
increased above unstimulated values at 500µM and 1000µM. While DHS007 was
consistent or lower than unstimulated, DHS008 had a spike at 10µM before returning
around unstimulated levels. When comparing the average control and DHR participants
across AMX concentrations (Figure 4-32), there were no significant differences observed.
There was a slight but not significant increase in DHS averages at 10µM, 500µM, and
1000µM AMX, and a slight decrease at 100µM, but none were significantly different
from unstimulated when analyzed by repeated measures ANOVA. Control participant
averages were very similar to unstimulated values. When a repeated measures ANOVA
was conducted on the control averages alone, the p value was not significant (> 0.05).
MFI for each individual participant (Figure 4-33) did not reveal any differences, other
than DHS007 slightly increasing as concentration increased, and DHS008 was very low
in comparison to the unstimulated values and the other participants (both control and
DHS). With the average MFI values (Figure 4-34), other than a very slight but not
significant increase at 500µM for the control participants, everything was very similar to
unstimulated values and there were no significant differences between group or
concentration. When analyzed by repeated measures ANOVA, neither control
participants or DHS participant MFI levels showed no significant differences between
treatment concentrations and unstimulated.
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Figure 4-31: Percent of CD3+ T cells expressing CD69 in individual control and
DHS participant PBMCs incubated with AMX
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Figure 4-32: Percent of CD3+ T cells expressing CD69 normalized to unstimulated
control, as a result of PBMCs incubated with culture media (unstimulated control)
and four concentrations of AMX
A repeated measures ANOVA was conducted to determine if any concentration had a
significant effect on CD69 expression by CD3+ T cells. Mauchly’s Test of Sphericity was
insignificant (p = 0.277) and therefore the assumption of sphericity was met, and
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therefore a Greenhouse-Geisser correction was not used. F(4,24) = 0.510, p = 0.729.
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures
ANOVAs were also conducted on CD3+ CD69+ control participants and DHS
participants separately. For control participants, Mauchly’s Test of Sphericity was
violated, therefore a Greenhouse-Geisser correction was used. F(1.281,3.842) = 0.043, p
= 0.897. For DHS participants, Mauchly’s Test of Sphericity was violated, therefore a
Greenhouse-Geisser correction was used. F(1.443,4.329) = 0.815, p = 0.461.
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Figure 4-33: MFI of CD3+ T cells expressing CD69 in individual control and DHS
participant PBMCs incubated with AMX
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Figure 4-34: MFI of CD3+ T cells expressing CD69 normalized to unstimulated
control, as a result of PBMCs incubated with culture media (unstimulated control)
and four concentrations of AMX
A repeated measures ANOVA was conducted to determine if any concentration had a
significant effect on CD69 expression by CD3+ T cells. Mauchly’s Test of Sphericity was
insignificant (p = 0.491), the assumption of sphericity was met, and therefore a
Greenhouse-Geisser correction was not used. F(4,24) = 0.155, p = 0.959. N(control
participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures ANOVAs
were also conducted on CD3+ CD69+ control participants and DHS participants
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a
Greenhouse-Geisser correction was used. F(1.531,4.593) = 1.232, p = 0.355. For DHS
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser
correction was used. F(1.916,5.748) = 0.073, p = 0.925.
With CD3+CD4+, in the individual percent (Figure 4-35), most participants were very
similar to unstimulated. With the control participants, Control005 increased above
unstimulated at 10µM but decreased back down to unstimulated by 1000µM AMX.
Control006 decreased at 1000µM, while Control007 increased at 1000µM. For the DHR
participants, DHS004 increased at 10µM, decreased below unstimulated at 100µM, then
returned to unstimulated values at 500 and 1000µM. DHS005 increased from below
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unstimulated at 10µM and 100µM to increase above unstimulated at 500µM and 1000µM
AMX. DHS007 was consistently lower than unstimulated across all concentrations, and
DHS008 was close to unstimulated. When comparing average values at the different
concentrations (Figure 4-36), there were no noticeable differences between the groups
and unstimulated. A repeated measures ANOVA indicated no significant differences
between any treatment groups and unstimulated for both control participants and DHS
participants. Control006 was slightly increased at 100µM, and DHS008 was low across
all concentrations similar to the other cell types. Individual MFI values did not reveal any
obvious differences between participants (Figure 4-37). Comparing average MFI values
(Figure 4-38) did not reveal any significant differences between control and unstimulated
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Figure 4-35: Percent of CD3+CD4+ T cells expressing CD69 in individual control
and DHS participant PBMCs incubated with AMX
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Figure 4-36: Percent of CD3+CD4+ T cells expressing CD69 normalized to
unstimulated control, as a result of PBMCs incubated with culture media
(unstimulated control) and four concentrations of AMX
A repeated measures ANOVA was conducted to determine if any concentration had a
significant effect on CD69 expression by CD3+CD4+ T cells. Mauchly’s Test of
Sphericity was insignificant (p = 0.471), the assumption of sphericity was met, and
therefore a Greenhouse-Geisser correction was not used. F(4,24) = 0.555, p = 0.697.
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures
ANOVAs were also conducted on CD3+CD69+ control participants and DHS participants
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a
Greenhouse-Geisser correction was used. F(1.257,3.772) =0.043, p = 0.893. For DHS
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser
correction was used. F(1.508,4.524) = 1.354, p = 0.330.
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Figure 4-37: MFI of CD3+CD4+ T cells expressing CD69 in individual control and
DHS participant PBMCs incubated with AMX
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Figure 4-38: MFI of CD3+CD4+ T cells expressing CD69 normalized to
unstimulated control, as a result of PBMCs incubated with culture media
(unstimulated control) and four concentrations of AMX
A repeated measures ANOVA was conducted to determine if any concentration had a
significant effect on CD69 expression by CD3+CD4+ T cells. Mauchly’s Test of
Sphericity was significant (p = 0.012), the assumption of sphericity was not met, and
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therefore a Greenhouse-Geisser correction was used. F(1.832,10.995) = 1.685, p = 0.230.
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures
ANOVAs were also conducted on CD3+CD69+ control participants and DHS participants
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a
Greenhouse-Geisser correction was used. F(1.384,4.151) = 0.699, p = 0.496. For DHS
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser
correction was used. F(2.073,6.219) = 1.638, p = 0.269.
CD3+CD8+ cell types did not show many individual differences with CD69 expression
(Figure 4-39); only control004 showed a slight increase as with increasing concentrations
with a slight decrease from 500µM to 1000µM, and DHS005 showed an increase as
concentration increased. No other participants visibly differed from the control. With the
average percent CD69 values (Figure 4-40), there were no significant differences found
with the repeated measures ANOVA, either when the data for control and DHS
participants was combined or when analyzed separately. There was a noticeable
difference at 100µM AMX between control and DHS participants, where the control
participant average was slightly higher, but this difference was not significant overall
with the repeated measures ANOVA. Student’s t-test conducted between the control and
DHS participants at 100uM had a p value of 0.069. With individual MFI values (Figure
4-41), all values were similar to unstimulated. When the average MFI values were
compared (Figure 4-42), no significant differences were observed with a repeated
measures ANOVA. However, there is a difference seen at 1000µM, where the DHS
participants mean MFI was slightly higher than control. While this difference was not
significant with the ANOVA, a one-tailed student’s t-test revealed this comparison to
have a p value of 0.0034.
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Figure 4-39: Percent of CD3+CD8+ T cells expressing CD69 in individual control
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Figure 4-40: Percent of CD3+CD8+ T cells expressing CD69 normalized to
unstimulated control, as a result of PBMCs incubated with culture media
(unstimulated control) and four concentrations of AMX
A repeated measures ANOVA was conducted to determine if any concentration had a
significant effect on CD69 expression by CD3+CD8+ T cells. Mauchly’s Test of
Sphericity was insignificant (p = 0.168), the assumption of sphericity was met, and
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therefore a Greenhouse-Geisser correction was not used. F(4,24) = 0.714, p = 0.590.
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures
ANOVAs were also conducted on CD3+ CD69+ control participants and DHS
participants separately. Repeated measures ANOVAs were also conducted on CD3+
CD69+ control participants and DHS participants separately. For control participants,
Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser correction was used.
F(2.026,6.079) = 0.019, p = 0.982. For DHS participants, Mauchly’s Test of Sphericity
was violated, so a Greenhouse-Geisser correction was used. F (1.439,4.318) = 1.420, p =
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Figure 4-41: MFI of CD3+CD8+ T cells expressing CD69 in individual control and
DHS participant PBMCs incubated with AMX
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Figure 4-42: MFI of CD3+CD8+ T cells expressing CD69 normalized to
unstimulated control, as a result of PBMCs incubated with culture media
(unstimulated control) and four concentrations of AMX
A repeated measures ANOVA was conducted to determine if any concentration had a
significant effect on CD69 expression by CD3+CD8+ T cells. Mauchly’s Test of
Sphericity was insignificant (p = 0.407), the assumption of sphericity was met, and
therefore a Greenhouse-Geisser correction was not used. F(4,24) = 1.028, p = 0.412.
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures
ANOVAs were also conducted on CD3+ CD69+ control participants and DHS
participants separately. For control participants, Mauchly’s Test of Sphericity was
violated, so a Greenhouse-Geisser correction was used. F(1.669,5.007) = 3.677, p =
0.107. For DHS participants, Mauchly’s Test of Sphericity was violated, so a
Greenhouse-Geisser correction was used. F(1.979,5.936) = 1.672, p = 0.265.
Similar patterns were seen with CD3- cells. With the individual participants (Figure 443), most were very similar to unstimulated. Control004 was slightly lower across all
concentrations than unstimulated, while Control007 decreased from unstimulated as
concentration of AMX increased. DHS007 was consistently slightly higher than
unstimulated at all concentrations. Overall, when the average values were compared
(Figure 4-44), no significant differences were observed with a repeated measures
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ANOVA. One small noticeable difference was seen again at 1000µM, where the DHR
percent CD69 value was slightly higher than control. While not significant in the
ANOVA, a student’s t-test at this concentration had a p value of 0.003. With individual
MFI values, a few differences are seen (Figure 4-45). For the most part, values were
consistent around unstimulated. DHS004 however increased from unstimulated as
concentration increased, and there was a sharp increase in the MFI of CD69 with
DHS005 at 100µM. DHS007 and DHS008 were consistently lower than unstimulated.
With the average MFI values (Figure 4-46), there were no significant differences seen.
The sharp increase of DHS008 is responsible for variability and an increase (but not
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Figure 4-43: Percent of CD3- PBMCs expressing CD69 in individual control and
DHS participant PBMCs incubated with AMX
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Figure 4-44: Percent of CD3- PBMCs expressing CD69 normalized to unstimulated
control, as a result of PBMCs incubated with culture media (unstimulated control)
and four concentrations of AMX
A repeated measures ANOVA was conducted to determine if any concentration had a
significant effect on CD69 expression by CD3- T cells. Mauchly’s Test of Sphericity was
insignificant (p = 0.437), the assumption of sphericity was met, and therefore a
Greenhouse-Geisser correction was not used. F(4,24) = 0.719, p = 0.587. N(control
participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures ANOVAs
were also conducted on CD3+ CD69+ control participants and DHS participants
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a
Greenhouse-Geisser correction was used. F(2.233,6.700) = 2.833, p = 0.126. For DHS
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser
correction was used. F(1.449,4.348) = 1.050, p = 0.396.
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Figure 4-45: MFI of CD3- PBMCs expressing CD69 in individual control and DHS
participant PBMCs incubated with SMX
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Figure 4-46: MFI of CD3- PBMCs expressing CD69 normalized to unstimulated
control, as a result of PBMCs incubated with culture media (unstimulated control)
and four concentrations of AMX
A repeated measures ANOVA was conducted to determine if any concentration had a
significant effect on CD69 expression by CD3- T cells. Mauchly’s Test of Sphericity was
significant (p = 0.022), the assumption of sphericity was not met, and therefore a
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Greenhouse-Geisser correction was used. F(1.603,9.621) = 0.646, p = 0.513. N(control
participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures ANOVAs
were also conducted on CD3+ CD69+ control participants and DHS participants
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a
Greenhouse-Geisser correction was used. F(1.611,4.834) = 2.157, p = 0.212. For DHS
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser
correction was used. F(1.481,4.443) = 0.477, p = 0.597.

4.3.5

Comparison of SMX and AMX Grouped Concentrations

Since four concentrations each of AMX and SMX were used, they were combined in
increasing concentrations to see if there was any effect on increasing concentration on the
isolated PBMCs from hypersensitive individuals. Control participants were not included
in this analysis. Percent CD69 expression and MFI of CD69 values were normalized to
unstimulated values. See Figures 4-47 to 4-54.
Across all cell types, there were no significant differences in percent of CD69 expression
or MFI of CD69 when drug concentration was increased. Overall, there did not seem to
be any trends that exceeded unstimulated values. Within CD3+ cell types, the second
concentration (C2) was consistently low in percent CD69 compared to unstimulated and
other concentrations, but nothing was found by repeated measures ANOVA to be
significant (Figure 4-47, 4-49, 4-51). There was a slight decrease from unstimulated in
the MFI of CD69 on CD3+CD4+ cells (Figure 4-50). Within the CD3- cell types, the
second concentration (C2) appeared to be very high, but also had high variability (Figure
4-53).
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Figure 4-47: Average percent of CD69 expression on CD3+ PBMCs isolated from
hypersensitive participants, combining SMX and AMX concentrations
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any
differences among the unstimulated and the increasing drug concentrations of drugs.
Mauchly’s Test of Sphericity was not violated. F(4,16) = 0.782, p = 0.553.
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Figure 4-48: Average MFI of CD69 on CD3+ PBMCs isolated from hypersensitive
participants, combining SMX and AMX concentrations
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any
differences among the unstimulated and the increasing drug concentrations of drugs.
Mauchly’s Test of Sphericity was not violated. F(4,16) = 0.130, p = 0.969.
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Figure 4-49: Average percent of CD69 expression on CD3+CD4+ PBMCs isolated
from hypersensitive participants, combining SMX and AMX concentrations
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any
differences among the unstimulated and the increasing drug concentrations of drugs.
Mauchly’s Test of Sphericity was not violated. F(4,16) = 1.468, p = 0.258.
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Figure 4-50: Average MFI of CD69 expression on CD3+CD4+ PBMCs isolated from
hypersensitive participants, combining SMX and AMX concentrations
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N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any
differences among the unstimulated and the increasing drug concentrations of drugs.
Mauchly’s Test of Sphericity was not violated. F(4.16) = 1.891, p = 0.161.
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Figure 4-51: Average percent of CD69 expression on CD3+CD8+ PBMCs isolated
from hypersensitive participants, combining SMX and AMX concentrations
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any
differences among the unstimulated and the increasing drug concentrations of drugs.
Mauchly’s Test of Sphericity was not violated. F(4,16) = 1.604, p = 0.222.
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Figure 4-52: Average MFI of CD69 of CD69 expression on CD3+CD8+ PBMCs
isolated from hypersensitive participants, combining SMX and AMX concentrations
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any
differences among the unstimulated and the increasing drug concentrations of drugs.
Mauchly’s Test of Sphericity was not violated. F(4,16) = 0.758, p = 0.568.
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Figure 4-53: Average percent of CD69 expression on CD3- PBMCs isolated from
hypersensitive participants, combining SMX and AMX concentrations
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N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any
differences among the unstimulated and the increasing drug concentrations of drugs.
Mauchly’s Test of Sphericity was not violated. F(4,16) = 0.475, p = 0.753.
2

CD3- MFI of CD69 normalized to
unstimulated

1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Unstimulated

C1

C2

C3

C4

Figure 4-54: Average MFI of CD69 expression on CD3- PBMCs isolated from
hypersensitive participants, combining SMX and AMX concentrations
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any
differences among the unstimulated and the increasing drug concentrations of drugs.
Mauchly’s Test of Sphericity was violated (p = 0.41), therefore a Greenhouse-Geisser
correction was used. F(1.480,5.921) = 0.559, p = 0.550.

4.3.6

Control and DHS Participant Response to Anti-CD3

In addition to analyzing the different concentrations of SMX and AMX compared to
unstimulated, I also analyzed whether there were any differences between control and
DHR participant response to anti-CD3 stimulation (Figures 4-55 to 4-62). To do this, all
participants were combined, because anti-CD3 was the positive control for all
participants regardless of drug type. Student’s t-tests were used to compare the percent
CD69 expression and MFI of CD69 on CD3+, CD3+CD4+, CD3+CD8+, and CD3- cells.
Overall, CD3- cells had a significantly lower percent expression of CD69 compared to the
CD3+ cells. When activated with anti-CD3, all participant CD3+ cells had an average
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percent CD69 expression of 33.10%, while CD3- had 1.27% (student’s t-test, one-tailed,
p <0.005). This was similar for MFI of CD69 – CD3+ cells had an average MFI of CD69
of 2.36, while CD3- had 1.27 (student’s t-test, one-tailed, paired, p < 0.01).
The only instance where there was a significant difference between control and DHS
participant response to stimulation with anti-CD3 was with the percent of CD3+ cells
expressing CD69 (Figure 4-57). In this case, 27.68% of CD3+CD4+ cells were
expressing CD69, which is significantly lower than the control participants, where
65.42% of CD3+CD4+ cells were expressing CD69 (student’s t-test, one-tailed, p =
0.043). Meanwhile, there were no significant differences in MFI of CD69 by CD3+CD4+
T cells in response to stimulation with anti-CD3 (student’s t-test, one-tailed, p = 0.38),
see Figure 4-58. There were no other significant differences between any other responses
to anti-CD3 in the other cell types analyzed (p > 0.05), see Figures 4-55 and 4-56, 4-58,
4-59 and 4-60, 4-61 and 4-62.
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Figure 4-55: Average percent of CD69 expression on CD3+ PBMCs isolated from
control and hypersensitive (DHS) participants stimulated with anti-CD3
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3stimulated values. Student’s t-test, one-tailed, p = 0.39.
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Figure 4-56: Average MFI of CD69 expression on CD3+ PBMCs isolated from
control and hypersensitive (DHS) participants stimulated with anti-CD3
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3stimulated values. Student’s t-test, one-tailed, p = 0.34.
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Figure 4-57: Average percent of CD69 expression on CD3+CD4+ PBMCs isolated
from control and hypersensitive (DHS) participants stimulated with anti-CD3
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N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3stimulated values. Student’s t-test, one-tailed, p = 0.049.
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Figure 4-58: Average MFI of CD69 expression on CD3+CD4+ PBMCs isolated from
control and hypersensitive (DHS) participants stimulated with anti-CD3
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3stimulated values. Student’s t-test, one-tailed, p = 0.22.
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Figure 4-59: Average percent of CD69 expression on CD3+CD8+ PBMCs isolated
from control and hypersensitive (DHS) participants stimulated with anti-CD3
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3stimulated values. Student’s t-test, one-tailed, p = 0.20.
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Figure 4-60: Average MFI of CD69 expression on CD3+CD8+ PBMCs isolated from
control and hypersensitive (DHS) participants stimulated with anti-CD3
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3stimulated values. Student’s t-test, one-tailed, p = 0.19.
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Figure 4-61: Average percent of CD69 expression on CD3- PBMCs isolated from
control and hypersensitive (DHS) participants stimulated with anti-CD3
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3stimulated values. Student’s t-test, one-tailed, p = 0.18.
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Figure 4-62: Average MFI of CD69 expression on CD3- PBMCs isolated from
control and hypersensitive (DHS) participants stimulated with anti-CD3
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3stimulated values. Student’s t-test, one-tailed, p = 0.12.
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4.3.7

Combining SMX Concentrations in Control and DHS
Participants

In addition to comparing the effect of individual concentrations of SMX to unstimulated,
the concentrations of SMX were combined by taking the average of percent CD69
expression and MFI of CD69 and compared to unstimulated (Figures 4-63 to 4-70).
Drug-stimulated values were normalized to unstimulated values. No significant
differences were found between control and hypersensitive participants stimulated with
SMX. However, in three instances, the drug-stimulated percent CD69 or MFI of CD69
values were observed to be lower than unstimulated: CD3+CD4+ percent CD69 (Figure 465), CD3+CD4+ MFI of CD69 (Figure 4-66), and CD3+CD8+ percent CD69 (Figure 467). All others appeared to be similar to unstimulated.
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Figure 4-63: Average percent of CD69 expression of CD3+ PBMCs isolated from
control and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of SMX
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare percent of
CD69 expression between control and DHS participants after exposure to SMX.
Student’s t-test, p = 0.38.
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Figure 4-64: Average MFI of CD69 expression of CD3+ PBMCs isolated from
control and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of SMX
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare MFI of CD69
expression between control and DHS participants after exposure to SMX. Student’s t-test,
p = 0.49.
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Figure 4-65: Average percent of CD69 expression of CD3+CD4+ PBMCs isolated
from control and hypersensitive (DHS) participants as a result of exposure to
combined concentrations of SMX
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare percent of
CD69 expression between control and DHS participants after exposure to SMX.
Student’s t-test, p = 0.38.
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Figure 4-66: Average MFI of CD69 expression of CD3+ PBMCs isolated from
control and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of SMX
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare MFI of CD69
expression between control and DHS participants after exposure to SMX. Student’s t-test,
p = 0.47.
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Figure 4-67: Average percent of CD69 expression of CD3+CD8+ PBMCs isolated
from control and hypersensitive (DHS) participants as a result of exposure to
combined concentrations of SMX
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare percent of
CD69 expression between control and DHS participants after exposure to SMX.
Student’s t-test, p = 0.42.
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Figure 4-68: Average MFI of CD69 expression of CD3+CD8+ PBMCs isolated from
control and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of SMX
N(control) = 2, N(DHS) = 2, ± SEM.Student’s t-test was used to compare MFI of CD69
expression between control and DHS participants after exposure to SMX. Student’s t-test,
p = 0.26.
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Figure 4-69: Average percent of CD69 expression of CD3- PBMCs isolated from
control and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of SMX
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare percent of
CD69 expression between control and DHS participants after exposure to SMX.
Student’s t-test, p = 0.43.
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Figure 4-70: Average MFI of CD69 expression of CD3- PBMCs isolated from
control and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of SMX
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare MFI of CD69
expression between control and DHS participants after exposure to SMX. Student’s t-test,
p = 0.33.

4.3.8

Combining AMX Concentrations in Control and DHS
Participants

All of the concentrations of AMX were combined to see if there was any effect between
unstimulated and AMX in general. Student’s t-tests were performed between control
AMX and DHS AMX values. No significant differences were found between these
values with any cell type (Figures 4-71 to 4-78).
All of the concentrations of AMX were combined to see if there was any effect between
unstimulated and AMX in general. Student’s t-tests were performed between control
AMX and DHS AMX values. No significant differences were found between these
values with any cell type (Figures 4-71 to 4-78). Similar to SMX results, there were no
significant differences found between control and hypersensitive participants stimulated
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with AMX. There were no instances where AMX-stimulated values appeared lower than
unstimulated.
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Figure 4-71: Average percent of CD69 expression of CD3+ PBMCs isolated from
control and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of AMX
N(control) = 4, N(DHS) = 4, ± SEM. Student’s t-test was used to compare percent of
CD69 expression between control and DHS participants after exposure to AMX.
Student’s t-test, p = 0.32.
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Figure 4-72: Average MFI of CD69 of CD3+ PBMCs isolated from control and
hypersensitive (DHS) participants as a result of exposure to combined
concentrations of AMX
N(control) = 4, N(DHS) = 4; ± SEM. Student’s t-test was used to compare MFI of CD69
expression between control and DHS participants after exposure to AMX. Student’s ttest, p = 0.38.
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Figure 4-73: Average percent of CD69 expression of CD3+CD4+ PBMCs isolated
from control and hypersensitive (DHS) participants as a result of exposure to
combined concentrations of AMX
N(control) = 4, N(DHS) = 4, ± SEM. Student’s t-test was used to compare percent of
CD69 expression between control and DHS participants after exposure to AMX.
Student’s t-test, p = 0.28.
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Figure 4-74: Average MFI of CD69 of CD3+CD4+ PBMCs isolated from control
and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of AMX
N(control) = 4, N(DHS) = 4; ± SEM. Student’s t-test was used to compare MFI of CD69
expression between control and DHS participants after exposure to AMX. Student’s ttest, p = 0.26.
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Figure 4-75: Average percent of CD69 expression of CD3+CD8+ PBMCs isolated
from control and hypersensitive (DHS) participants as a result of exposure to
combined concentrations of AMX
N(control) = 4, N(DHS) = 4, ± SEM. Student’s t-test was used to compare percent of
CD69 expression between control and DHS participants after exposure to AMX.
Student’s t-test, p = 0.35.
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Figure 4-76: Average MFI of CD69 of CD3+CD8+ PBMCs isolated from control
and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of AMX
N(control) = 4, N(DHS) = 4; ± SEM. Student’s t-test was used to compare MFI of CD69
expression between control and DHS participants after exposure to AMX. Student’s ttest, p = 0.11.
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Figure 4-77: Average percent of CD69 expression of CD3- PBMCs isolated from
control and hypersensitive (DHS) participants as a result of exposure to combined
concentrations of AMX
N(control) = 4, N(DHS) = 4, ± SEM. Student’s t-test was used to compare percent of
CD69 expression between control and DHS participants after exposure to AMX.
Student’s t-test, p = 0.14.
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Figure 4-78: Average MFI of CD69 of CD3- PBMCs isolated from control and
hypersensitive (DHS) participants as a result of exposure to combined
concentrations of AMX
N(control) = 4, N(DHS) = 4; ± SEM. Student’s t-test was used to compare MFI of CD69
expression between control and DHS participants after exposure to AMX. Student’s ttest, p = 0.38.

4.4 Cytokine Analysis Results
Cytokines IFN-y, IL-4, IL-9, IL-13, IL-17A, and IL-22 were analyzed by a custom
Luminex kit by Bio-Rad. These cytokines were analyzed from the cell culture
supernatant. Any cytokine secretion, if seen at all, occurred in anti-CD3 stimulated
samples. Most results were highly variable due to only one sample of four having any
detectable level of cytokine.
IFN-7 was the only cytokine that had values in all conditions, however it is likely that
most of these were extrapolations (specifically values under approximately 19 pg/ml).
Anti-CD3 stimulation of both control and DHS PBMCs resulted in IFN-y secretion
(Figure 4-79). Control004 had some secretion of IL-4, and IL-17A in the media (Figure
4-80, 4-83). Anti-CD4 stimulation resulted in secretion of IL-4 and IL-9 in one DHS
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participant only, and not in the controls (Figure 4-80, 4-81). IL-22 was also secreted
when control and DHS participants were stimulated with anti-CD3 (Figure 4-84).
It is important to note that if a bar is missing from the bar graph, it signifies that the result
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Figure 4-79: Observed concentration of IFN-y in pg/ml after incubation of PBMCs
isolated from control and AMX-hypersensitive participants in anti-CD3, media
(negative control), 100uM AMX, and 500uM AMX
N(control) = 4, N(DHS) = 4.
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Figure 4-80: Observed concentration of IL-4 in pg/ml after incubation of PBMCs
isolated from control and AMX-hypersensitive participants in anti-CD3, media
(negative control), 100uM AMX, and 500uM AMX
N(control) = 4, N(DHS) = 4.
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Figure 4-81: Observed concentration of IL-9 in pg/ml after incubation of PBMCs
isolated from control and AMX-hypersensitive participants in anti-CD3, media
(negative control), 100uM AMX, and 500uM AMX
N(control) = 4, N(DHS) = 4.
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Figure 4-82: Observed concentration of IL-13 in pg/ml after incubation of PBMCs
isolated from control and AMX-hypersensitive participants in anti-CD3, media
(negative control), 100uM AMX, and 500uM AMX
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Figure 4-83: Observed concentration of IL-17A in pg/ml after incubation of PBMCs
isolated from control and AMX-hypersensitive participants in anti-CD3, media
(negative control), 100uM AMX, and 500uM AMX
N(control) = 4, N(DHS) = 4.

Observed concentration IL-22 (pg/ml)

124

4
3.5
3
2.5
2
1.5
1
0.5
0
anti-CD3

media
Control

100uM

500uM

DHS

Figure 4-84: Observed concentration of IL-22 in pg/ml after incubation of PBMCs
isolated from control and AMX-hypersensitive participants in anti-CD3, media
(negative control), 100uM AMX, and 500uM AMX
N(control) = 4, N(DHS) = 4.
The cytokine concentrations of IL-4, IL-9, IL-13, IL-17A, and IL-22 were secreted in
much lower concentrations than IFN-γ in response in anti-CD3 stimulation (Figure 4-85).
However, not all participants had cytokines secreted when stimulated with anti-CD3. All
participants secreted some amount of IFN-γ upon stimulation (Figure 4-86). For example,
DHS005 was the only participant secreting IL-4 (Figure 4-87) and IL-9 (Figure 4-88), no
other participants secreted detectable amounts of these cytokines. DHS005 also secreted
greater amounts of cytokines when secreted with anti-CD3 compared to the other
participants. Most participants secreted some small amount of IL-13 and IL-17A (Figures
4-89 and 4-90).
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Figure 4-85: Average observed concentration of each cytokine analyzed in result to
incubation of PBMCs isolated from control and AMX-hypersensitive participants
with anti-CD3
N(control) = 4, N(DHS) = 4.
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Figure 4-86: Observed concentration of IFN-y (pg/ml) in response to incubation of
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3
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Figure 4-87: Observed concentration of IL-4 (pg/ml) in response to incubation of
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3
N(control) = 4, N(DHS) = 4.
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Figure 4-88: Observed concentration of IL-9 (pg/ml) in response to incubation of
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3
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Figure 4-89: Observed concentration of IL-13 (pg/ml) in response to incubation of
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3
N(control) = 4, N(DHS) = 4.
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Figure 4-90: Observed concentration of IL-17A (pg/ml) in response to incubation of
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3
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Figure 4-91: Observed concentration of IL-22 (pg/ml) in response to incubation of
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3
N(control) = 4, N(DHS) = 4.

129

Chapter 5

5

Discussion

5.1 Aims and Objectives
Adverse drug reactions account for approximately 5% of all hospital admissions and
affect millions annually.5 Of these ADRs, DHRs account for approximately 20%.11,12
Despite this, diagnosing DHRs is still difficult, resulting in overdiagnosis, reliance on
substitute antibiotics, and limited understanding of the underlying mechanisms.3,18,27
There are several competing hypotheses that attempt to explain how these DHRs occur
(reviewed in § Pathophysiology of DHRs), however there is no consensus.
The aim of this thesis is to study and characterize lymphocytes from peripheral blood
samples from participants with clinical presentations suggestive of delayed-type drug
hypersensitivity reactions by comparing them to healthy controls. Since the underlying
cause and pathophysiology of T cell-mediated hypersensitivity reactions is still not fully
understood, the goal was to use a combination of techniques to study drug-specific
lymphocytes. Previous findings suggest that there are different T cells involved with
different physical presentations of drug allergy. We hypothesized that differences in
activated peripheral T cell subsets and types of mediators released have a direct impact
on the clinical presentations of DHRs. We wanted to determine if there are any cell types
or cytokines involved in the different clinical presentations we observed and recruited.
We specifically chose sulfamethoxazole (SMX) and penicillin due to the high number of
cases typically referred to Dr. Rieder’s clinic. Due to less than optimal cell count for the
3

H-thymidine and flow cytometry experiments, and RBC contamination in PBMCs

leading to inconsistent cell counts in cytokine analysis, the results are inconclusive.
However, this work has led to discovery of better methods and insights for
improvements, optimization, and future studies.

5.2 SMX Parent Drug was Best Form of Sulfamethoxazole
Sulfamethoxazole, which inhibits the synthesis of tetrahydrofolic acid in bacteria,244 is
metabolized in the liver by N-acetyltransferases and N-glucoronul-transferase, resulting
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in the production of non-toxic metabolites.243 CYP-450 can also metabolize small
amounts of SMX into two metabolites, SMX-NO and SMX-HA.247,248 Since SMX, SMXNO, and SMX-HA can be involved in the immune response,60,122,243 it was important to
determine if any of these will cause damage to the PBMCs they would be incubated with.
We know that SMX-HA is a reactive metabolite that can lead to greater cell death, so we
needed to see if it would cause greater cell death than it would show cell activation. Our
preliminary experiments used SMX and SMX-HA because SMX-NO was too unstable
for use under the experiment conditions.
First, I used PBMCs isolated from one volunteer and incubated these PBMCs with either
unstimulated media, three concentrations of SMX, or three concentrations of SMX-HA.
In the highest concentration of SMX-HA (100µM) used, there was a decrease in percent
cell viability (Figure 3-1), but since sample size was only 1, I repeated the highest
concentration with PBMCs isolated from two additional volunteers and found a
significant decrease in percent cell viability after incubation (Figure 3-2). Therefore, we
chose SMX since it did not negatively affect cell viability like SMX-HA.

5.3 54 Hour Incubation was the Optimal Length of Time
We needed to determine what the optimal length of time for incubating PBMCs with
universal mitogen to minimize cell death and to show maximum activation. Since we
used CD69 as an activation marker, this would show how CD69 is expressed over a time
course and allow us to decide how long to incubate the PBMCs with drugs for. If the
incubation time is not optimal, we would not see the maximum number of CD69activated cells, and it would be more difficult to see an effect since dividing cells would
closely resemble non-dividing cells. This experiment was modeled after a similar
experiment by Beeler et al.,295 however we added an extra timepoint and used control
participants only.
I isolated PBMCs from three volunteers. After incubating the isolated PBMCs for
intervals of 18 hours for a total of 90 hrs with anti-CD3, and staining for viability and
CD69, we found a decrease in live cells (Figure 3-3). A rANOVA revealed that there was
a significant decrease in cell viability as incubation time increased.
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For determining the optimum length of incubation time for best CD69 expression, no
significant timepoints were found for any of the cell types (CD3+, CD3+CD4+,
CD3+CD8+) examined (Figures 3-4 to 3-9). There was considerable variability across all
timepoints, specifically in the MFI values. There were some noticeable but not significant
increases at 54 hours for CD3+ and CD8+ cells (Figures 3-3, 3-5), while CD4+ cells had
the highest CD69 expression at the 18-hour timepoint.
Overall an incubation time of approximately 54 hours was chosen as a compromise
between cell viability and CD69 expression. If closer to 90 hours was chosen, that would
have left only approximately 50% of cells in the sample viable, even if there is no
significant difference between 54 hours and 90 hours for percent CD69 expression.
For this experiment, both anti-CD3-stimulated and unstimulated samples were prepared
for flow cytometry analysis, and the unstimulated values were subtracted from the
stimulated values. However, it would be wise to repeat this experiment with a 0-hour
timepoint to better normalize the timepoints in addition to stimulated and unstimulated
samples at each timepoint.

5.4 Participant Recruitment
For this study, patients were recruited from Dr. Michael Rieder’s drug safety clinic at
London Health Sciences Centre, Victoria Hospital in London, Ontario. This research
would not be possible without this direct access to ADR patients.
While we are fortunate to have potential access to a wide number of people of all ages
seeking an in vitro toxicity assay for potential ADRs, there are some pitfalls. Typically,
these participants are referred to the clinic by their primary care physician due to a
suspected previous ADR to a drug their primary care physician is interested in
prescribing them. However, many times these participants have no real recollection of
when the reaction occurred, let alone the specifics including type of resulting skin
reaction or how many days after ingestion of the drug that the reaction occurred. This is
the primary reason why some cases are described as “rash, unspecified.” These patients
are included due to a positive LTA. The LTA test typically occurred sometime in the
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previous 10 years before this study. It has been previously reported that drug-specific T
cells can be re-activated after 12 years since previous exposure122 or over 20 years since
previous exposure.301 Recruitment was challenging, as the participants often would not
answer phone calls, phone number was out of service and not updated with hospital, no
interest, no availability, or difficulty accessing RRI due to location of home or work.
We opted to test adult former patients (>18 years of age at the time of study) due to more
easily obtained consent and a larger volume of blood drawn. Children and adolescents
would be more complicated due to parental consent, for example parents might not be
inclined to have blood drawn from their children for research. Children would also have
to be taken out of school, or their parents would have to drive them before or after, while
adults are usually more flexible with schedules and transportation.
Out of all of Dr. Rieder’s former patients, many were eliminated immediately if the result
of their LTA was negative. From all of the patients with positive LTAs, we excluded all
those not positive to sulfamethoxazole and penicillin. I verified the final selected
patients’ LTA results, confirmed their eligibility to participate with Dr. Rieder, called
former patients for consent to participate, and explained the contents of the letter of
information and consent package over the phone (see Appendix § Letter of Information).
In addition, participants were also recruited directly from Dr. Rieder’s clinic at the same
time as LTA testing. These participants were asked to participate either because they had
a strong history indicative of a delayed type ADR to either sulfamethoxazole or
penicillin, or because they already had testing and were doing a re-test for a different
drug.
The participant pool consisted of middle-aged women with the exception of one man.
Many of the participants eligible to participate were women; I did call prospective male
participants, however many did not return my phone call. In contrast, the women I spoke
to seemed very eager to participate in the study. It is also worth noting that while my
study is biased towards women, ADRs are also more prevalent in women. There are a
few possible explanations to why more women were recruited. The first being that more
women tend to access health care services and have more consultations with their GP
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than men do, and in effect are prescribed more antibiotics. The second reason is women
are more often diagnosed with an ADR than men. Overall, women are prescribed more
antibiotics than men,32 especially for conditions such as RTIs,32,33 and UTIs.32 Women
also seek primary care much more than men do.34,302,303 Women also have physiological
differences, such as higher levels of CYP450, different levels of hormones, different rates
of drug conjugation, and differences in body mass.35–38
Recruitment of participants also depends on the location of the patient themselves. The
clinic often acquires samples from referred patients who live outside of London, often
around Toronto or elsewhere throughout Southwestern Ontario. Many of these patients
have a positive LTA and a history of ADR to the drugs that we are interested in, however
often it is not possible to acquire a sample due to the participant residing outside of
London. This can be due to a variety of reasons, some of which were experienced over
the course of the recruitment of patients. Often, private clinics (ie. Life Labs or
community health services) are inconsistent with their ability to draw blood for this
lab/clinic. In addition, patients are often not motivated enough to participate, since it
often involves driving to University Hospital or Robarts, which is inconvenient for many
in addition to not wanting an extra blood test. Many of the patients were able to
participate in this study by simply happening to be in the area at the time.
It would open up many more opportunities for patient recruitment if we could access
these samples outside of the London area, or arrange with other clinics around London to
be able to draw the blood to make it easier for participants who work during the day.
Currently, University Hospital can do draws from about 8 am until 4 pm daily, but other
private clinics might be open on the weekends or in the evenings. In the future it would
be ideal to make arrangements with other hospitals or blood-drawing clinics in other
cities to access a greater number of participants.

5.5 Defense of Drug Choice
Sulfamethoxazole and penicillin were chosen as our culprit drugs of choice, rather than a
survey of all drugs tested for in the clinic, because these two drugs are some of the most
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commonly tested for. We were able to obtain a large list of potentially eligible
participants, some of which had consented to be a part of Dr. Rieder’s database.
However, there are some of the downsides of these drug choices, one example being
sulfamethoxazole. SMX is a frequently prescribed antibiotic for UTIs,304 which are
mostly seen in women. While they can and do occur in men, typically men do not suffer
from as many UTIs due to increased length of urethra,305–307 among other reasons
including urethral opening proximity to vaginal mucosa compared to the dry epithelium
of the glans penis.305,306
Choosing the appropriate reactive metabolite was important (see section Determining
Best Form of Sulfamethoxazole). As previously mentioned, SMX-NO, and SMX-HA are
reactive metabolites of SMX. SMX-NO has previously been used in studies.243 SMX-HA
is used in Dr. Rider’s LTA analyses. Currently in the lab, we have stock of SMX-HA and
SMX, however SMX-NO is unstable, so it would not be as useful. We found SMX-HA to
negatively affect cell viability (Figures 3-1 and 3-2). In addition, it would be interesting
to use liver microsomal metabolites rather than the AMX parent drug, to allow for
reactive metabolites to be used in the experiment.102,257

5.6 Scintillation Counting
Beeler et al. suggest that a SI of at least 2 is a moderately positive result for DHR when
using the LTT, while a SI of 3 is a strong positive result.295
Scintillation counting was performed on both SMX and AMX groups of participants,
after incubation of 54 hrs (established as incubation length for flow cytometry) and 4
days. I found none of the concentrations of SMX or AMX caused a significant increase in
SI at either timepoint (Figure 4-1, 4-3, Figure 4-5, 4-7). In addition, the age of the
participant did not correlate with any noticeable increase in SI.
In some of the raw data for the scintillation counting, the cpm were low for anti-CD3stimulated PBMCs and some for drug-stimulated samples were indistinguishable from
unstimulated wells. I learned later on that there was an issue with cell counting and there
was increased RBC contamination after the experiment was complete. I did not know I
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was making this error and it was not corrected in time. We had previously attempted this
when testing different mitogens and T cell stimulants (ex. anti-CD3, PHA, etc) and the
results were better. In order to improve on this and obtain the results shown in other
successful LTT studies, the incubation time should be extended to six days and the cell
counting optimized to decrease RBC contamination.
Another possibility in the future would be to use CFSE (carboxy fluorescein succinimidyl
ester) instead of 3H-thymidine incorporation. CFSE is a common flow cytometry-based
assay to assess cell proliferation, and it works by staining desired cells with CFSE before
incubation, and quantifying the labelled cells by number of divisions. There is a
progressive halving of fluorescence with each cell division.308 There are several benefits
to using CFSE over 3H-thymidine incorporation. First, there is no radiation required and
therefore no radiation permits or special training would be required. In addition, since it’s
a flow cytometry-based assay, it can discriminate between cell types, for example
between CD4+ vs CD8+ cell types dividing, if those surface markers are also stained
for.308 CFSE is also stably and uniformly incorporated into cells, meaning cells can be
cultured for weeks and still have measurable levels of CFSE remain in the cells.309–313
Previous studies have used CFSE to stain T cells for cell proliferation in response to drug
stimulation after six-122,295,314 or seven-315 day incubations.
One potential downside of this method would be cost – the flow cytometer is rented with
a set rate. One bottle of 3H-thymidine can last a long time, one well only requires 1ul, and
use of the scintillation counter is free to the lab. For the CFSE analysis by flow
cytometry, a new experiment would have to be set up with CFSE, in addition to all other
desired fluors (for example, to differentiate T cells from PBMCs, and different T cell
subsets), with our own FMO and isotype controls. A separate flow cytometry
appointment would need to be set up aside from CD69 experiments, since staining for
CD69 is done after only 54 hours of incubation, instead of six days.

5.7 Flow Cytometry
Flow cytometry was used with the stimulated PBMCs to determine which type of cell
(CD3+, CD3+CD4+, CD3+CD8+, CD3-) was expressing CD69. These PBMCs were gated
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according to cell surface marker expression as dot plots (Figure 4-5) and as histograms
(Figure 4-6).
First, flow cytometry results were used to screen participants. Both cell viability and
percent CD3 cells of total cells acquired were examined. To include participants, it was
decided that the majority of PBMCs analyzed had to be alive (>50% cell viability after
staining with fixable viability dye). With SMX participants (consisting of four DHR
participants and three control participants), two DHS participants had viability less than
50% (Figure 4-7), and one control participant (Figure 4-8). It is not clear why these
particular participants (DHS001, DHS002, and Control002) had low cell viability. For
AMX testing, there were five DHR participants and four control participants. All
participants had cell viability greater than 50% (Figures 4-9 and 4-10) so no AMX
participants were excluded on this basis.
In addition to cell viability criteria, participants were also excluded based on percent of
CD3+ T cells acquired. If this percentage was too low, there would not be enough to see
cells in gates further in the flow cytometry analysis. Typically, CD3+ T cells are
approximately 70% of the composition of PBMCs.78–82,316,317 However, since there is
individual variation between individuals, we removed participants with less than 30% of
CD3+ cells acquired. Because of this, for SMX participants, DHS001, DHS002, and
Control002 were removed – these were previously removed due to low cell viability. Out
of the AMX participants, DHS006 was removed for a very low percentage of CD3+ T
cells. This is likely because once the blood was drawn, the laboratory that drew the blood
refrigerated the sample, causing red blood cell contamination in the PBMC layer during
Ficoll separation. This tube was centrifuged for longer to attempt to remove more RBCs,
however the RBC count was still very high which was especially noticeable in the flow
cytometry results.
For SMX participants, there was no significant increase in percent CD69 or MFI of CD69
across any of the cell types (CD3+, CD3+CD4+, CD3+CD8+, CD3-, see Figures 4-15 to 418, 4-19 to 4-22, 4-23 to 4-26, 4-27 to 4-30, respectfully). There was some variability in
the groups at each concentration, however there were not enough participants to draw
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conclusions. At the 100µM and 200µM SMX concentrations for DHS participants, one of
the participants had very low cell numbers at these concentrations so these samples had to
be removed.
There were few participants (N < 3 in each control and DHS) in this portion of the study,
therefore no statistics could be performed. Ideally more participants would be recruited
with hypersensitivities to SMX. To improve collection and results, red blood cell
contamination would be reduced at the counting stage, and more cells would be acquired
by flow cytometry (upwards of 50 000 cells).
Similar to SMX results, there was no significant increase in percent CD69 or MFI of
CD69 across any of the cell types (CD3+, CD3+CD4+, CD3+CD8+, CD3-), see Figures 431 to 4-34, 4-35 to 4-38, 4-39 to 4-42, 4-43 to 4-46. There were some noticeable
increases in a few instances in each cell type, however none of these increases were
significant. There were two instances in this analysis where there was a noticeable
difference between control and DHS. At 100µM AMX, the percent of CD69 on control
CD3+CD4+ cells was higher than the DHS cells. This is unexplained and could be
attributed to several things, including too few participants and low cell count. In addition,
with CD3- cells, there was greater CD69 expression on DHS cells compared to control
cells at 1000µM. There were no other noticeable differences at the other concentrations.
While this difference could also be attributed to error, this concentration is also high and
could have had an effect on CD69 expression. Again, there should be a greater number of
participants, more cells acquired, and use of an isotype control to confirm this.
In addition to looking at each concentration individually, the increasing concentrations
were grouped as concentration 1 (C1, 10µM AMX and 100µM SMX), concentration 2
(C2, 100µM AMX and 200µM SMX), etc (Figures 4-47 to 4-54). This analysis was done
with results from the DHS participant group across both SMX and AMX participants.
The goal was to see if there are any noticeable increases across increasing concentrations.
These were separated according to cell type, percent CD69 expression and MFI of CD69,
similar to previous analyses. Similar to other results, there were no significant differences
between unstimulated and increasing concentrations across any cell types.

138

There were only a few noticeable, but not significant, differences. First with CD3+CD4+
percent CD69, at C2 (200µM SMX, 100µM AMX) there was an observable decrease
below unstimulated and the other concentrations, while the other concentrations (1, 3, 4)
showed no difference from unstimulated. CD3+CD4+ MFI of CD69 had a slight decrease
across concentrations, however none of these concentrations differed from unstimulated.
With CD3- MFI of CD69, C2 had large variability, which was different from the other
concentrations, which did not differ from unstimulated. It is not fully known why these
small differences occurred, however as with the previous analyses, a larger participant
group, improved methods, the results would be more accurate.
Another analysis that was done was to look at how the control and DHS participants
responded to anti-CD3 stimulation (Figures 4-55 to 4-62). Since anti-CD3 is a positive
control for all of the participants across both drug types, all participants were combined
regardless of which drug they had a hypersensitivity to. First, CD3- had a lower percent
CD69 compared to CD3+ cells, which is still consistent considering while some cells in
the CD3- population might express CD69, they may not express this protein in the same
capacity as T cells, or some may not express it at all.
There was one instance in this analysis where there was a difference between the percent
of CD69 being expressed between control and DHS cells. CD3+CD4+ control PBMCs
expressed a significantly higher percent of CD69 when compared to DHS participants
when stimulated with anti-CD3 (Figure 4-57), however this difference was not reflected
in the MFI of CD69 (Figure 4-58). This means that more cells expressed similar numbers
of CD69. The reason for this is unknown so far.
AMX concentrations were combined to see if control or DHS participant PBMCs reacted
differently to incubation to amoxicillin in general, regardless of concentration (Figures 471, 4-72 to 4-77, 4-78). There were no significant differences between control and DHS
participants in either percent of CD69 or MFI of CD69 across all cell types. While this
analysis does not take into account how the PBMCs would respond in different
concentrations, it is reasonable to expect some differences across the concentrations that
would affect CD69 expression.
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Beeler et al. (2008) demonstrated that 1.9% of CD4+ T cells from drug-allergic
participants expressed CD69 in response to sulfapyridine, 1.1% in response to tetanus
toxoid, and 0.1% to media. In our flow cytometry analysis, we did not see this. However,
when looking at very few PBMCs, our analysis could be only seeing a few stimulated T
cells. Increasing the number of PBMCs analyzed would increase the number of
CD4+CD69+ T cells, which would make the difference between CD69- and CD69+ cells
more distinct. Deciding on where to place the gate for the CD69- T cells was decided by
FMOs, however isotype controls should be used to place the gate more accurately. This is
because isotype controls reduce non-specific binding of fluorescent-labeled antibodies.
Even if we are seeing this 1-2% activation in T cells, it could be lost in the murky area
between CD69+ and CD69- due to lack of isotype controls.
With flow cytometry, starting cell count does not matter as much as cells are counted
during analysis, and analysis is stopped once a certain threshold is reached. In the future,
a greater number of cells should be analyzed, instead of 10000, closer to 100 000
PBMCs. This, coupled with decreasing RBC contamination, could show more CD69+
cells if they exist in the sample, making a positive response more noticeable.
There are also some improvements that can be made to the protocol, which can be
established with improvements in the number of fluorescent channels on a flow
cytometer, or the availability of such a flow cytometer at Western University. The
fluorescent antibodies that were used for this experiment included CD3-APC, CD4-PE,
CD8-BV421, and CD69-PE-Cy7. CD3 is a pan-T cell marker, CD4 is present on Th cells,
CD8 is present on CTLs, and CD69 is a T cell activation marker.105,225,229,318 These four
markers are for broad classes of T cells and activation, and we could get more specific
than this. In the future, we could look at activation of more specific types of Th cells,
including Th1, Th2, Th9, Th17, Th22, and Treg cells by flow cytometry by introducing
other markers to the flow panel.
This study is very underpowered. For the flow cytometry work alone, if looking at drug
and control, we would need N=28, or N=14 each for patient participants and controls, for
each drug, for 80% power. This power calculation was performed by using the
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differences in percent of CD69 T cells in response to drug stimulation observed in the
study conducted by Beeler et al.295 Adding in different clinical presentations would
increase the number of participants. With six conditions, drugs, and participant/control
groups, the required participant number increases to 72, with N = 12 per condition. The
work completed so far has only 8 participants in total and is therefore incredibly
underpowered. In addition to making adjustments to the methods, many more participants
would need to be recruited. One benefit though is that this experiment could be
considered a pilot project, to further provide insight into future studies.

5.8 Luminex
A custom Luminex assay purchased from Bio-Rad was used to assess the concentrations
of IFN-y, IL-4, IL-9, IL-13, IL-17A, and IL-22 in the cell culture supernatant. Four DHS
participants and their corresponding controls were selected from the AMX participants.
DHS006 and Control006 were not chosen due to high RBC contamination and low
percentage of CD3+ cells observed in flow cytometry results.
The majority of the samples that expressed any level of cytokine were those stimulated
with anti-CD3. Anti-CD3 promotes cell proliferation which could lead to greater amounts
of cytokines released. Few cells in tested cultures would produce undetectable amounts in
control and drug treatments. However, these results were highly variable because usually
only one or two participants of the four had a measurable release of cytokines. None of
the samples incubated with 100µM and 500µM AMX secreted detectable levels of
cytokines, and most of the control (media) did not secrete any detectable levels of any of
the cytokines. Only DHS005 secreted low but detectable levels across all six cytokines
evaluated.
Given that there are likely inconsistent numbers of cells across samples, a protein
quantification would be required to compare samples to each other. The total protein
acquired would be divided by the amount of cytokine secretion to normalize to protein
content. However, only the supernatant was used and it was frozen to accumulate enough
samples for Luminex. The cells were centrifuged and the supernatant was collected off
the top, and the plate and cells were discarded. In addition, the media used was
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supplemented with 10% human serum, which contains protein. Our original concept was
to conduct a total protein quantification on the remaining supernatant used for Luminex,
and use RPMI 1640 + 10% human AB serum as background. This background protein
quantification would be subtracted from the protein content of the samples. We attempted
to do this and tested the controls and standard curve with the protein quantification kit. It
was recommended to use a buffer without protein, such as 1% PBS. After analyzing the
standard curve prepared in both PBS and RPMI 1640 + 10% human AB serum, the media
curve was very warped, and it was suggested by BioRad that the media and serum were
not compatible with the kit. It is also a possibility that the proteins in the kit increased the
total protein content higher than the upper limit of the kit. In the future, it would be
beneficial to ensure the PBMC concentration is the same among all participants with
more accurate cell counting. In addition, conduct protein quantification alongside
isolating and freezing the supernatant, so that cells could be lysed and a total protein
quantification could be done on lysed cells. Alternatively it could be done as it was, and
the supernatant could be frozen and analyzed later. It would also be beneficial to leave
out the serum if we will be doing a protein quantification.
Other methods we had previously considered included ELISAs (enzyme-linked
immunosorbent assay) and ELISpot (enzyme-linked immunospot) assays. An ELISpot is
similar to an ELISA, however the cells are bound to the bottom of a 96-well plate, and
the cytokines being released are also bound to the bottom of the plate, near the secreting
cell. When the dye is applied, the cell secreting the cytokine being analyzed turns blue.
The number of cells secreting the cytokine can be counted. This method would be useful
if we tried cloning drug-specific T cells.104 ELISAs could be used, however each kit for a
single cytokine was approximately $600. For this initial attempt, Luminex was less
expensive. However, if this experiment continues in the future, the ELISAs may be a
more economical solution. In addition, the ELISA kit has the ability to measure
additional proteins, including granzyme B, which is secreted by cytotoxic T cells.
Granzyme B, for example, is not measurable by the Bio-Rad customizable Luminex kit
we used. This would be relevant due to the involvement of cytotoxic T cells in StevensJohnson Syndrome, for example Chung and Hung 2010, Murata et al. 2008, among
others.270,272
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In addition to surface phenotyping greater populations of T cells by flow cytometry, we
can also look at cytokine secretion using flow cytometry. While Luminex is a viable
solution, it could be beneficial to try intracellular cytokine staining. One downside to this
is that the flow cytometer currently available is able to examine 14 colours. We would
have to carefully choose which cytokines to analyze in order to accommodate the
viability dye, cell surface markers, and intracellular dyes. However, to accomplish all of
this at once by flow cytometry, the staining would take more time and the flow cytometer
would require more fluorescent channels, depending on how many Th cell types are being
analyzed and how many cytokines would be looked at.
To correctly power this study for Luminex, a survey of the literature for the difference
between baseline and stimulated cytokine concentrations for each cytokine would need to
be done. A smaller difference would require additional participants to support a
conclusion.

5.9 Future Studies
There are many future directions that can be taken with this project. Regarding
participant recruitment, it would be prudent to focus more on recruiting more age- and
sex-matched controls. In this current study, the gender profiles of the DHR participants
differed from those of the controls, as well as the average age was significantly older in
the DHR compared to the controls. Another interesting avenue to explore would be
matching the reason the drug was taken. For example, if one participant had a DHR to
SMX taken for a UTI, then the control would have taken SMX for a UTI but did not have
a reaction.
An interesting direction this research could take is to genotype HLA-type participants in
addition to the in vitro testing done. There are many GWAS (Genome-Wide Association
Studies) from throughout the globe,319–323 including some in Canada.324 It would be
beneficial to genotype adult patients recruited, and also extend this to paediatric patients
as well. These GWAS help to identify culprit genes that contribute to the development of
ADRs, and are often specific to origin/ethnicity. Genotyping is a huge component of
personalized medicine. By phenotyping people who have or have had ADRs, we can look
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for patterns between genes (specifically HLA genes), drug type and clinical presentation.
This would be extremely beneficial to people who are looking to take a specific drug.
With so few participants, this is a low-powered study, especially considering the vast
numbers of different skin reactions that exist and recruiting more people over time to
increase the number of hypersensitive participants as well as controls to increase the
power would reveal more promising results.
Children are some of the most common users of prescription antimicrobials.325 It would
be very beneficial to include children into this analysis. Children are not just smaller
versions of adults: the physiology of a child and their ability to metabolize drugs is
different than that of an adult, in addition to several other differences.326,327 While there
could be a genetic component to penicillin hypersensitivity in children, it could be
another underlying pathway resulting in adverse reactions occurring.328 One of the main
reasons children were excluded from this study is because of the volume of blood
required for the study. With adults, we drew approximately 15 ml of peripheral blood,
while in children typically we must draw less because they are smaller. Improving the
methods, for example by combining the current methods into one large flow cytometry
panel, could decrease the total number of isolated PBMCs required to acquire the same
information. This would decrease the amount of blood required to be drawn, which could
open up this experiment to consenting and assenting children and teenagers.
In addition to collecting and plating PBMCs for Luminex, I originally isolated CD3+ cells
for plating for cytokine release. However due to the cost of reagents for one 96-well plate
and prioritizing PBMCs over isolated T cells, the supernatant for these T cells is still
frozen. This is important since there would be no RBC contamination unlike in the
PBMC experiments. The cell count is consistent across all samples and these samples
could be tested reliably without protein quantification. While limited by not including
CD3- derived cytokines, it would be interesting to see T cell only derived cytokines
profiles. Ideally this analysis would be run alongside PBMCs.
Our current study asked participants who had a DHR diagnosed in previous years, similar
to previous reports (for example Beeler et al. 2007).295 It would be interesting to continue

144

this research in DHR patients who are currently undergoing a DHR, and also get leftover
skin biopsy and blister fluid samples from active lesions. Some previous studies have
done this, and have examined activated T cells and cytokines present in both peripheral
blood and skin/blister fluid with promising results.275 They also analyzed peripheral
blood during an active DHR and after resolution. This is important since it can
demonstrate important diagnostic markers.

5.10 Conclusions
Overall, we cannot draw conclusions due to too few subjects and the need for different
experimental approaches. However, there are several improvements that can be made that
have been proposed. In the future it would be prudent to adjust the methods, including
using flow cytometry to measure proliferation instead of scintillation counting. We could
also expand the number of T cell subsets we analyze, by both increasing the surface
markers by flow cytometry and the cytokines tested using a bead-based detection assay. It
would be interesting to look at different drugs in addition to sulfamethoxazole and beta
lactam antibiotics, to learn more about the role drug type has with DHRs. This study
could span years to accumulate enough participants and increase power. There is much
work to be done in the field of drug hypersensitivity; efforts put towards faster
identification and detection of DHRs can contribute to decreased healthcare burden and
increased quality of life.
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Appendices
List of Abbreviations
ADR – adverse drug reaction
AGEP – acute generalized exanthematous pustulosis
AMX – amoxicillin
APC – antigen presenting cell
BCR – B cell receptor
BSA – body surface area
CBZ – carbamazepine
CCR – chemokine receptor
CD – cluster of differentiation
CLA – cutenaous leukocyte antigen
Cpm – counts per minute
CTL – cytotoxic T cell
DAMP – danger-associated molecular patterns
DC – dendritic cell
DHR – drug hypersensitivity reaction
DIHS – drug-induced hypersensitivity syndrome
DNA – deoxyribonucleic acid
DRESS – drug rash with eosinophilia and systemic symptoms
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DRESS – drug reaction with eosinophilia and systemic symptoms
EM – erythema multiforme
FACS – fluorescence-activated cell sorter
FasL – Fas ligand
GP – general practitioner
GVHD – Graft vs Host Disease
GWAS – genome wide association study
HLA – human leukocyte antigen
IFN-y – interferon-gamma
Ig – immunoglobulin
IL – interleukin
ILC – innate lymphoid cell
LTA – lymphocyte toxicity assay
LTE – lymphocyte transformation test
MHC – major histocompatibility complex
MPE – maculopapular exanthemas
MRSA – methicillin resistant staphyllocaucus aureus
NK – natural killer
NKT – natural killer T cells
NSAID – non-steroidal anti-inflammatory drugs
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p-i – direct pharmacological interaction of drugs with immune receptors
PAMP – pathogen-associated molecular patterns
PBMC – peripheral blood mononuclear cell
PBS – phosphate buffered saline, pH = 7.2
PE – phycoerythrin
PE-Cy7 – phycoerythrin cyanine-7
Pen – penicillin
PMA – phorbol myristate acetate
R – receptor (ie. IL-4R)
rANOVA – repeated measures analysis of variance
RBC – red blood cell
RNA – ribonucleic acid
RPMI – Roswell Park Memorial Institute (media)
RTI – respiratory tract infection
SI – stimulation index
SJS – Stevens-Johnson Syndrome
SJS – Stevens-Johnson Syndrome
SLE – systemic lupus erythematosus
SMX – sulfamethoxazole
SMX-HA – sulfamethoxazole hydroxylamine
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SMX-NO – nitrososulfonamide
Strep – streptomycin
Tc – cytotoxic T cell (also see CTL)
TCR – T cell receptor
TEN – Toxic Epidermal Necrolysis
TGF-b – tumour growth factor
TH – helper T cell
TMP – trimethoprim
TNF – tumor necrosis factor
TNF-b – tumour necrosis factor
Treg – regulatory T cells
UTI – urinary tract infection
ViD – viability dye
WHO – World Health Organization
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Professor, Departments of Paediatrics, Physiology & Pharmacology
and Medicine, Schulich School of Medicine and Dentistry, Western
University
Department of Paediatrics
London Health Sciences Centre

Study Coordinator:
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Graduate Student:
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Title of Study: Characterizing T-cell phenotype in patients with hypersensitivity reactions to
sulfonamides and beta-lactam antibiotics

Background
Adverse drug reactions are a serious problem and are among the top five causes of all deaths in
Canada and the United States. We know that some people who take a drug suffer an adverse
reaction while others can take the same drug without any adverse effects. Some of these adverse
reactions are mediated by cells in the immune system that circulate through the blood. We would
like to learn more about how these cells differ between patients with a history of drug reaction
and those without.
Purpose of Study
The purpose of our research is to prevent adverse drug reactions and the subsequent skin rashes
through improved understanding of the physical features of involved immune cells and their
secretions. These studies will help to find out what role different cell types and their respective
secretions have in predicting who will have adverse drug reactions and what type of adverse skin
reaction will result.
Since not all of the immune cells and cell secretions involved in different responses to drugs have
been discovered yet, we would like to bank your biological sample to study in the future. This way,
we can go back and test different types of cells present in your sample, or look at different
secretions that those cells produce when stimulated with the drug.
The exact plan for these future studies is not known at this time since it will depend on other
discoveries being made in the area of pharmacological and immunological research.
Invitation
You are being invited to participate in a study looking at immune cells in your peripheral blood
(specifically, blood from a vein in your arm), and then have the unused sample of your cells
isolated from blood stored for future use in research studies. This process is referred to as
biobanking.
Participation
Before you decide to consent, it is important for you know why we wish to collect and bank your
peripheral immune cells and what will be done with them. This consent form will tell you what
will be collected and stored, where it will be stored, who will have access to it, how it may be used
in the future, and the possible benefits, risks, and discomforts associated with providing a sample.
If you wish to participate in this study, you are invited to sign this form. Participation in this study
is voluntary, therefore you have the right to refuse to allow us to obtain a blood sample and/or
have your isolated immune cells banked. Refusing to participate or have your cells banked will not
affect your participation in this study nor will refusing to participate in the study as a whole affect
your present or future medical care.
Please take time to read the following information carefully and to discuss it with your family,
friends, and doctor before you decide.

Procedures
As part of this study, a small amount of your blood (approximately 15-20 millilitres, or 3-4
teaspoons) will be drawn using a needle from a vein in your arm.
Once the blood is collected, the peripheral blood mononuclear cells (PBMCs; immune cells that are
in circulation through arteries and veins) will be isolated. The cells will be examined for how they
respond to stimulation with the drug that caused the adverse reaction. Then, we would like to take
a portion of the isolated PBMCs and freeze them for future analysis. Upon consent, your samples
will be labelled with a unique numeric code so that your name will not be attached to the sample.
Only the study’s Principal Investigator and his designates will hold the key containing your unique
numeric code with your identifying information. This sample will be held frozen at Robarts
Research Institute, Western University.
We are also asking your permission to keep some information obtained from your medical
records. This information is only pertinent to the adverse drug reaction you experienced to
sulfamethoxazole or beta-lactam antibiotics. Only the relevant information obtained from these
records will be stored in our secure study databases located at Robarts Research Institute. This
information will be identified using the same study identity number as the biological sample. No
information that could identify you personally will be included. Only the study investigators will
have access to the database.
Every measure will be taken to ensure your privacy. The cells you provide will only be used for
research described in this consent form. You will not receive the results of this or any future tests.
Your participation in this study will not become part of your medical record. The analyses
conducted by our investigators are focused on the response of cells upon stimulation by the
specific drug you have an adverse reaction to and a control stimulant. Therefore it is extremely
unlikely that we will uncover any new information relevant to your health or overall
wellbeing. However, in the rare event that this occurs, the biobank will be requested to re-identify
you so that we can notify your physician of our findings.
Responsibilities
After your blood sample has been taken you do not need to do anything else to participate in this
study.
Risks and Discomforts
Blood withdrawing is identical to any blood sample taking for routine blood tests at a hospital or a
medical lab. The possible harms and discomforts of the study mostly involve the collection of the
blood sample. There may be some slight pain and discomfort when the needle is inserted into the
vein for blood collection, and some minor bleeding, bruising, swelling, or feeling faint or dizzy
after it is removed.

Benefits
The research that may be done with your biological sample is not expected to benefit you or your
family members directly. However, we hope that the information gained from these studies can be
used in the future to improve the safety and efficacy of beta-lactam antibiotics and
sulfamethoxazole.
Withdrawal
It is possible to withdraw from the study at any stage upon your request. All your samples will be
properly destroyed and data will be deleted.
Confidentiality
Protecting your privacy is our number one priority. Your rights to privacy are legally protected by
federal and provincial laws that require safeguards to ensure that your privacy and personal data
are respected. These laws also give you the right of access to the information that has been
provided and, if need be, an opportunity to correct any errors in this information. In most cases,
your personal information or information that could identify you will not be revealed to any third
party, including your family members and your physician, without your expressed consent.
You will be assigned a unique study code number as a participant in this study. This number will
not include any personal information that could identify you (for example it will not include your
Ontario Health Insurance Card number, or Social Insurance Number, your initials, etc.). Only this
number will be used on any research-related information collected about you during the course of
this study, so that your identity will be kept confidential. Only the Principal Investigator, the study
coordinator, and the person collecting your blood sample will have access to the names of
participants in this study. Lists of participants will be kept locked in the office of the study
coordinators. All computer files will be kept encrypted and locked with restricted access
passwords known only to the investigators. Information about the drugs you take and your blood
sample will be sent to our analysis center, at the Robarts Research Institute, for analysis.
No information or records that disclose your identity will be published, nor will any information
or records that disclose your identity be removed or released without your consent unless
required by law.
Name, address, and phone number are collected in the rare instance that we need to contact you
regarding any unclear information. This extra contact will be minimal, and we do not expect to
contact every patient enrolled.
Since your sample and information will be kept for many years or until it is used entirely or
withdrawn, we will update our security measures for protecting your data and for preserving your
sample as they become available.

Contact Person(s) for Participants
If you have any questions about the study and/or treatment and care, you may contact Dr.
Abdelbaset (Baset) Elzagallaai, the study coordinator
or Christine Caron
No Waiver of Rights
You do not waive any legal rights by signing this consent form.

Consent Form – Research Copy
Title of Study: Characterizing T-cell phenotype in patients with hypersensitivity reactions to
sulfonamides and beta-lactam antibiotics
I have read the accompanying letter of information and have had the nature of the study explained
to me and I agree to participate in the study. All questions have been answered to my satisfaction.
Participant’s Date of Birth

Participant’s Name (please print)

Participant’s (or Guardian’s) Signature
Date

Name of Person Obtaining Informed Consent (please print)

Signature of Person Obtaining Informed Consent
Date

Consent Form – Participant Copy
Title of Study: Characterizing T-cell phenotype in patients with hypersensitivity reactions to
sulfonamides and beta-lactam antibiotics
I have read the accompanying letter of information and have had the nature of the study explained
to me and I agree to participate in the study. All questions have been answered to my satisfaction.
Participant’s Date of Birth

Participant’s Name (please print)

Participant’s (or Guardian’s) Signature
Date

Name of Person Obtaining Informed Consent (please print)

Signature of Person Obtaining Informed Consent
Date
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Curriculum Vitae
Academic Background
September 2017 – Western University
August 2020
Master of Science in Pathology and Laboratory Medicine
student under the supervision of Dr. Michael Rieder
January 2014 –
Algoma University
April 2017
Undergraduate student in Honours Bachelor of Science in
Biology, minor in Psychology
Awards and Scholarships Received
2018
Dr. Frederick Winnett Luney Graduate Research Award
2017
NSERC-USRA Scholarship
Algoma University Dean’s Honour List
2016
Algoma University Academic Achievement Scholarship
NSERC-USRA Scholarship
Algoma University Dean’s Honour List
2015
Algoma University Academic Achievement Scholarship
NSERC-USRA Scholarship
Algoma University Dean’s Honour List
2014
Lake Superior State University Dean’s List
2013
Lake Superior State University Canadian Student Entrance
Scholarship
Sault Ste. Marie Zonta Scholarship
Kewadin Club Scholarship
Work Experience
September 2018 –
present

Graduate Teaching Assistant (full time, 140 hours per semester)
– Western University, Department of Biology: Introductory
Biology (BIOL1001/1201A, BIOL1002/1202A) skills sessions B
teaching assistant, involves co-leading approximately 40
students through a wet lab environment, grading assignments,
proctoring midterms and final exams, entering grades

May 2017 –
August 2017;
May 2016 –
August 2016;
May 2015 –
August 2015,

NSERC Undergraduate Student Research Assistant – Algoma
University: Received NSERC-USRA grant to work in Algoma
University’s plant biochemistry lab under the supervision of Dr.
Isabel Molina on projects involving the study of suberin
deposition in poplar trees

September 2015 –
April 2016

Research Assistant – Algoma University, Department of Biology:
Worked in plant biochemistry lab at Algoma University under
the supervision of Dr. Isabel Molina, studying suberin deposition
in poplar tree studies
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January 2015 –
December 2015

Teaching Assistant – Algoma University, Department of Biology:
Introductory Chemistry (CHMI1006) course teaching assistant;
duties involved helping students, grading tests, quizzes,
assignments, and holding tutorial sessions for the classes

September 2014 –
December 2014

Teaching Assistant – Algoma University, Department of Biology:
Introductory chemistry (CHMI1006) lab teaching assistant;
duties included supervising the students during lab experiments,
answering questions, and helping the lab instructor

September 2014 –
April 2016

Tutor – Algoma University: Tutor for a variety of subjects,
including general chemistry and organic chemistry

Research Experience
September 2017 – Western University – London, Ontario: MSc student
present
• Supervisor Dr. Michael Rieder
• Project involves studying pathophysiology of drug
hypersensitivity reactions, specifically culturing,
stimulating, and staining immune cells, and assessing
phenotype and cytokines
2015 – 2017
Algoma University – Sault Ste. Marie, Ontario: NSERC-USRA
Scholarship
• Supervisor Dr. Isabel Molina
• Involved in continual research experiments surrounding
Populus sp. wounding experiments and mutant analysis
August 2016,
University of California San Diego – San Diego, California
August 2017
• Part of NSERC-USRA scholarship
• Supervisor Dr. Laurie Smith, collaboration with Dr. Isabel
Molina
• Collecting and phenotyping corn leaves as part of
National Science Foundation project on drought-resistant
maize
2016 – 2017
Algoma University – Sault Ste. Marie, Ontario: Thesis student
• Supervisor Dr. Isabel Molina
• Involved in determining gene responsible for unique bark
phenotype in Populus 717 mutant using forward genetics
and to determine whether mutation is related to suberin
deposition
2015 – 2016
Algoma University – Sault Ste. Marie, Ontario
• Supervisor Dr. Isabel Molina
• Plant Biochemistry
• Hired part-time to begin growing cuttings of mutant
Populus ssp. 717 mutant and performing lipid analyses on
suberin and associated waxes, while also performing
general lab duties such as TLC on other lab projects
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Conference Experience
June 2019

April 2019
March 2019

June 2018
May 2018

April 2018

March 2017

Canadian Society of Pharmacology and Therapeutics Joint Annual
Conference, “From Base to Summit: Pharmacology at its Peak”,
Calgary, Alberta
Presented poster Investigating the Pathophysiology of T-Cell
Mediated Drug Hypersensitivity Reactions
London Health Research Day, London, Ontario
• Presented poster Investigating the Pathophysiology of T-Cell
Mediated Drug Hypersensitivity Reactions
Western University Department of Pathology Research Day,
London, Ontario
• Presented poster Investigating the Pathophysiology of T-Cell
Mediated Drug Hypersensitivity Reactions
Robart’s 5th Annual Research Retreat, London, Ontario
• Presented poster Investigating the Pathophysiology of T-Cell
Mediated Drug Hypersensitivity Reactions
Canadian Society of Pharmacology and Therapeutics Joint Annual
Conference, “Translating Innovative Technology to Patient Care”,
Toronto, Ontario
• Presented poster Investigating the Pathophysiology of T-Cell
Mediated Drug Hypersensitivity Reactions
London Health Research Day, London, Ontario
• Presented poster Investigating the Pathophysiology of T-Cell
Mediated Drug Hypersensitivity Reactions
Western University Department of Pathology Research Day,
London, Ontario
• Presented poster Investigating the Pathophysiology of T-Cell
Mediated Drug Hypersensitivity Reactions
Ontario Biology Day 2017 Undergraduate Conference at
Laurentian University, Sudbury, Ontario
• Presented undergraduate thesis poster Characterization of
a Mutant Poplar Hybrid (Populus sp.) with an Abnormal Bark
Phenotype
•

Leadership, Outreach, and Volunteer Experiences
October 2018—
present

May 2018

Vice President of Social Events with Western Pathology
Association
• Planning social events for undergraduate and graduate
students as well as staff and faculty in the Pathology
department to help with teambuilding and morale
Volunteer at Science Rendezvous event with the Western
Pathology Association’s “Crime Scene Investigation” booth at
Western University, London, Ontario
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April 2017
2015—2016
April 2016
January 2015—
April 2016
September
2014—
April 2015
September
2014—December
2014

Volunteer at Sault Ste. Marie’s Science Festival “Hangar After
Dark” event at the Canadian Bushplane Heritage Centre, Sault
Ste, Marie, Ontario
President of the Algoma University Biology Club
Science Fair at Algoma University
• Presented overview of ongoing research conducted in Dr.
Isabel Molina’s laboratory
General Chemistry Teaching Assistant
• Created and conducted tutorial sessions for first year
students
Community Ecology Lab Volunteer
• Duties included sorting and counting seeds of various
species after collection from field for future analysis and
experimentation
General Chemistry Lab Teaching Assistant
• Aided students in performing lab experiments for first
year general chemistry

